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1 Introduction
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1.1 Protein cages
Nature has since long served as a great source of inspiration in biomedice and
biotechnology and the use of naturally occurring structures has shown great
potential  as  nanoscaled  building  blocks  and  biotemplates  for  diverse
nanotechnology  applications.  The  use  of  proteins  as  multivalent  multi-
functional  carriers  for  biotechnology  applications  is  experiencing  rapid
development.  Protein cages  are container-like protein architectures formed
from  protein  subunits  that  self-assemble  into  nearly  monodisperse  size
distribution  and  whose  functionality  can  be  tailored  by  introduction  of
chemical modifications or by genetic engineering. Naturally available protein
cages, such as viral capsids, small heatshock proteins and ferritins provide a
privileged template for engineering modifications. These nanodevices can be
loaded  with  chemotherapeutics  and/or  contrast  agents,  and  thus  develop
theranostic devices of great clinical value. They come in a wide variety of
sizes,  stability  and  functionalities  and  work  by  providing  a  protected
environment for their cargoes  (Uchida et al., 2007). Protein cages serve as
multipurpose  containers  for  the  transport  of  viral  payloads  (Cann,  2012),
biomineralization  (Theil  et  al.,  2013),  protein  folding  (Saibil,  2008) and
degradation  (Kish-Trier  et  al.,  2013),  enzyme encapsulation  (Sutter  et  al.,
2008) and can even work as catalysis microenvironment (Maity et al., 2016;
Milne,  2002),  but find their  most prominent application in the biomedical
field  as  drug-delivery  systems (DDS)  (Molino  & Wang,  2014).  Typically,
protein cages  self  assemble in  highly symmetrical  arrangements  based on
6 
helical, icosahedral, cubic or tetrahedral symmetries with three topologically
distinct regions: the interior, the exterior or the interface between subunits.
These interfaces provide a platform for insertion of modifications allowing
for customizable applications. There are few other nanoplatforms that offer
simultaneously biocompatibility, control over size and shape, and the ability
to  modify  and  combine  functionalities.  Their  application  in  the
biotechnological and biomedical field are only limited by one’s imagination
(Molino & Wang, 2014; Sasaki et al., 2017; Uchida et al., 2007).
Some noteworthy examples of the use of protein cages are described in the
literature:
I. Kramer et al. have reported the use of an engineered ferritin nanocage
for the synthesis of silver nanoparticles to overcome the issue of size
polydispersity  and  low  crystal  ordering  of  physical  nanoparticle
synthesis.(Kramer et al., 2004);
II. Falvo et al.  have described the use of an innovative antibody-drug
conjugate  for  the  treatment  of  melanoma  using  a  ferritin  cage
encapsulating  the  anticancer  drug  cisplatin  conjugated  with
monoclonal  antibodies  (mAb)  to  the  human  melanoma-specific
antigen  Chondroitin  sulfate  proteoglycan  4  (CSPG4).(Falvo  et  al.,
2013);
III. Flenniken et al. demonstrate that Heatshock protein (Hsp) cage from
Methanococcus  jannaschii can  be  used  to  confer  cell-specific
targeting  of  mammalian  cells  through  combination  of  genetic  and
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chemical modifications. Hsp was conjugated on its outer surface with
a tumor vascular  targeting peptide  or  anti-cluster  of  differentiation
(CD) 4 antibodies and on its inner surface with fluorescent molecules,
thus conferring the ability to simultaneously incorporate cell targeting
and imaging agents  within  a  single  protein cage  (Flenniken et  al.,
2006);
IV. Of  note  is  the  work  carried  by  Millan  et  al.,  where  cowpea
chloroticmoottle  virus  (CCMV)  capsid  was  used  to  encapsulate
smaller  paramagnetic  micelles  containing  a  compound  complexed
with Gd(III) or Zn(II) phtalacyanine for their use as contrast agents
for magnetic resonance imaging (MRI) (Millán et al., 2014).
Nevertheless, protein cages find their most striking application as DDS. The
uniform size, multifunctionality, biocompatibility and biodegradability push
them to the frontiers of drug-delivery  (MaHam et al.,  2009).  All  kinds of
DDS, both synthetic (silica, metallic, polymers, gels) and natural (proteins,
lipids,  sugars),  have been developed to address the issues of conventional
drugs  and  improve  their  pharmacological  properties  (Safari  &  Zarnegar,
2014).  As  the  medical  world  is  undergoing  a  transition  from  traditional
medicine to personalized medicine, more and highly versatile scaffolds for
DDS are needed, as well  as deeper understanding of their  properties. The
potential of conventional drugs in clinic is sometimes hampered due to poor
pharmacodynamics  –  what  the  drug  does  to  the  body,  including  its
mechanism of action – and pharmacokinetics – what the body does to the
drug, commonly divided in  4 phases:  absorption,  distribution,  metabolism
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and excretion  (Levy & Bauer, 1986). The development of appropriate DDS
can overcome barriers at any of those levels and bring drugs to therapeutic
areas otherwise unaccessible. A striking example where the development of
DDS is the of the utmost necessity is in cancer therapy. Upon administration,
anticancer drugs are distributed throughout the body usually with significant
off-site  effects  that  are  responsible  for  the  grave  side-effects  of  cancer
therapy. This reduces the effectiveness of the treatment as it limits  it to a
tolerable dose with sub-optimal amount of on-target drug (Cho et al., 2008).
Another  common  limitation  to  anticancer  drugs  is  their  short  “time  of
action”, i.e., the time available to be in contact with their intended target and
perform  their  action.  This  can  result  from  a  rapid  clearing  from  the
bloodstream by the kidneys/immune system or from their metabolization into
inactive  forms.  Furthermore,  drugs  can  have  poor  water  solubility  and
relatively short shelf-stability.  (Cho et al.,  2008; MaHam et al.,  2009). All
these issues can be addressed with the development of advanced, tailored
DDS.
When  compared  to  their  non-proteic  counterparts,  protein-based  DDS
perform better at various levels:  proteins raise less biocompatibility issues
and can be exploited to  bypass the defenses  of the immune system; they
usually  have  a  well  characterized  atomic  structure;  when  assembled  into
cages  are  characterized  by  narrow  size-distribution  because  of  rigid
geometrical constraints; they can be easily submitted to conjugation at any of
the  conceptual  interfaces  by  adding  chemical  compounds,  antibodies,
oligosaccharides  or  lipids,  or  any  conceivable  combination  of  these,
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depending  on  the  intended  application;  they  can  be  modified  by  genetic
engineering,  either  to  add  specific  conjugation  sites  or  to  alter  intrinsic
characteristics of the protein scaffold itself; and they allow for large scale
production  using  relatively  simple  recombinant  expression  in  bacterial
systems (Molino & Wang, 2014; Todd et al, 2013).
Over  30  therapeutically  relevant  compounds  have  been  investigated  with
protein-based DDS, such as the classic anticancer model drugs doxorubicin
(Simsek & Akif Kilic, 2005), rapamycin and colchicine, others compounds
such  as  progesterone,  glucocorticosteroids,  or  even  metal  ions  as  cobalt,
manganese, cadmium. Currently, a wide range of protein-based platforms are
being investigated for the treatment of various cancers, infectious diseases,
chronic diseases and autoimmune diseases (Kuruppu et al., 2015; Lee et al.,
2015; Vannucci et al., 2012; Z. Yang et al., 2007). A particularly successful
case  of  a  protein-based  conjugate  that  reached  clinics  is  the  albumin-
paclitaxel nanoparticle (Abraxane ®) that has been recognized as one of the
first approved protein-based nanoparticle for human use by the United States
Food and Drug Administration (US FDA) (Todd et al., 2013). This success
inspires researchers to pursue the development of other innovative and more
efficient protein-based nanocarriers.
1.2 The ferritin scafold
Ferritin  was  first  described  by  the  German  pharmacologist  Oswals
Schmiedeberg in 1894, who described it as an iron-rich component in horse
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livers. Later, in 1937, it was purified from horse spleen and characterized by
the Czech biologist Vilém Laufberger who proposed ferritin to act as an iron
depot  in  the  organism.  Early  studies  of  ferritin  were  possible  due  to  its
distinct  biochemical  characteristics:  stability  at  high temperatures,  relative
insolubility  in  ammonium  sulfate  solutions  and  its  crystallization  with
cadmium salts (Alkhateeb et al., 2013).
Alongside  with  the  research,  the  term  ferritin as  evolved  and  presently
ferritin describes a family of proteins, ubiquitous in all life forms with the
notable exception of yeast, whose physiological role as the cellular repository
of excess iron is unique. Ferritin’s role can be seen as that of a tiny organelle
for its ability to store iron and to release it in a controlled manner, avoiding
toxicity  by  excess  iron.  Ferritin  can  be  found  in  both  extracellular  and
intracellular  compartment:  although  mainly  cytosolic,  it  can  be  found  in
mitochondria, nucleus or free in the serum  (Andrews, 2010). The cytosolic
ferritins’  key  contribution  for  iron  homeostasis  is  reflected  by  its
ubiquitousness,  but  the  physiological  function  of  secreted  ferritin  remains
unclear. Elevated levels of serum ferritin have been linked to inflammation,
angiogenesis and tumors, and thus considered a marker for those conditions
(Meyron-Holtz  et  al.,  2011;  Wang  et  al.,  2010).  Members  of  the  ferritin
family of proteins share characteristic structural features: the presence of a
conserved fold made of a four-helix bundle domain in each subunit and the
assemble  of  twenty-four  monomeric  units  in  a  roughly  spherical  macro-
structure resembling a cage. This translates in the appearance of an hollow
interior  cavity  that  provides  an  environment  sheltered  from  the  external
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conditions. In nature the cavity is used to sequester iron in a non-reactive,
biomineralized form and to serve as a cellular stock of iron for biological
reactions, such as integration of cofactors for iron proteins (heme, FeS, mono
and diiron). The iron biomineralization reaction also provides an antioxidant
effect, acting as a depot for iron and oxidants arising from damaged proteins.
(Theil et al., 2013; Uchida et al., 2010)
Other than storing functions, ferritins have catalytic functions. The active site
is called the ferroxidase center (FOC) and it catalyzes the oxidation of Fe(II)
into Fe(III),  reducing either  dioxygen or  hydrogen peroxide  to  synthesize
Fe2O3•H2O, forming an iron-core within the protein shell (Theil et al., 2013).
The  ferritin  family  of  proteins  is  subdivided  in  three  sub-classes,  with
different morphological and functional characteristics: DNA-binding protein
from starved  cells  (Dps),  bacterioferritins  (Bfr)  and  the  classical  ferritins
(Andrews, 2010).
Dps protein is the most dissimilar within the family. It has the ability to bind
DNA non-specifically  and functions  mostly  in  ferrous  iron  detoxification.
Rather than storage, Dps acts as oxidative stress protecting factor, most likely
to avoid DNA oxidative damage. As such, Dps protects the cell from reactive
oxygen species (ROS) generated by the Fenton reaction: Fe2+ + H2O2  Fe➔ 3+
+ OH− + •OH (Zhao et al., 2002). In these proteins, the FOC sits between two
subunits at the two-fold axis interface instead of being located within the four
helix bundle motif  (Ilari et al., 2000). Another striking feature of Dps is its
smaller size that accounts for it being referred as mini-ferritin, as to contrast
with the other members of the family – the macro-ferritins. Dps structure is
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composed of twelve subunits instead of the canonical twenty-four, forming a
cage  with approximately  9.5  nm outer  diameter  and a  significantly lower
iron-storage  capacity  (Haikarainen  &  Papageorgiou,  2010).  The  crystal
structure also revealed a characteristic 23 point symmetry that contrasts with
the classic 432 symmetry found in other ferritins members, the absence of the
short  final  E helix,  and the presence of a  short  helix  within the BC loop
(Grant et al., 1998).
Bacterioferritin resembles classic ferritin in almost all aspects. It performs the
same biological role as canonical ferrritins but its distribution among species
is restricted to the bacterial  and archaeal domains of life  (Andrews et  al.,
1991). It retains the 24-meric quaternary structure and the typical four helix
domain enclosing the FOC in each subunit as well as the final short E helix
(Frolow et al., 1994). Its most notable difference is the presence of 12 heme
groups within the protein shell, located at the dimer two-fold interface. The
role of the heme group is unclear. but is thought to be involved in the release
of iron from the iron-core (Frolow et al., 1993; Weeratunga et al., 2009).
Classical ferritins are the archetype of the ferritin family of proteins and can
be  found in  all  domains  of  life.  Their  cage  structure  is  composed  of  24
subunits assembled in a rhombic dodecahedron and, similarly to Bfr, they
have the capacity to store-iron in a compact iron core within the protein shell.
Each monomer folds in a four helix bundle motif with a long loop connecting
helices B and C plus a fifth short helix at the C-terminal pointing inwards the
cavity  (Andrews, 2010; Theil et al., 2006). The FOC is located within the
four  helix  bundle  with  most  residues  involved  in  the  ferroxidase  activity
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conserved between classical and Bfrs. The subunits assemble in a 24-meric
cage of around 450 kDa with an outer diameter of approximately 12 nm and
an inner diameter of around 8 nm.(Arosio et al., 2017; Harrison & Arosio,
1996) The  assembled  ferritin  can  be  formed  by  distinct  but  homologous
subunits, like the case of human ferritin, where different contents of L and H
subunits (L for light and H for heavy) co-assemble to form heteropolymers
optimized for iron incorporation and mineralization. Different ratios of L to
H subunits are are found throughout the various human tissues  (Levi et al.,
1987). The topological distribution of monomers in the 24-mer protein shell
results in a 432 point symmetry, with eight hydrophilic pores at the three-fold
symmetry axis, and six hydrophobic channels at the four-fold symmetry axis.
The channels  at  the three-fold axis  have been proposed to  serve as entry
channels for Fe(II) atoms (Alkhateeb & Connor, 2013; Arosio et al., 2017).
1.2.1 Probe encapsulation
Understanding the keys aspects of probe loading, entrapment and release is
of major importance for the use of ferritin-based DDS. Molino and Wang
(2014)  have  reviewed  and  summarized  the  strategies  used  for  drug
encapsulation  and  release  for  protein  cages  (Figure  1.1):  drug-loading
strategies  include  assembly/disassembly,  covalent  modification,  pore  entry
and  physical  interactions.  Drug-releasing  strategies  include  pH  triggered
release,  reducing  environment,  biodegradation  and  diffusion  (Molino  &
Wang, 2014). Most of these strategies have been attempted using a variety of
ferritin scaffolds. 
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Figure 1.1 –  Summary of  strategies  for  drug loading and release  using protein
cages. Image adapted from Molino et al. (Molino & Wang, 2014)
Assembly/Disassembly
The  loading  of  payloads  within  the  ferritin’s  cavity  can  be  achieved  by
exploiting the association-dissociation properties of the multimeric shell, thus
inducing  the  disassembly  into  subunits  followed  by  reassembly  in  the
presence  of  the  wanted  cargo  under  selected  experimental  conditions.
Payload  entrapment  is  then  achieved  as  a  physical  confinement  into  the
cavity under reassembly conditions. Nevertheless, given the high stability of
the 24-mer species, the dissociation process requires harsh conditions, such
as acidic pH values, with suboptimal loading and low protein recovery. The
association-dissociation  process  is  in  fact  dependent  upon  an  extensive
network of  interactions  at  the  subunit  interfaces,  comprising  hydrophobic
interactions,  salt  bridges  and  hydrogen  bonds  that  can  be  eventually
manipulated  by  genetic  engineering  in  order  to  affect  the  strength  of
intersubunit contacts (Huard et al., 2013). In this framework, the incomplete
understanding of the physical aspects governing the assembly/disassembly of
ferritins poses a challenge for successful application of this strategy. Human
ferritin has been the most frequently used to entrap a number of compounds.
Its disassembly is induced by lowering the pH to around 2.0 and re-assembly
achieved  by  restoring  it  to  neutral  pH.  Under  this  procedure,  only  pH
resistant compounds can be loaded, and the re-assembly process has been
reported  to  be  incomplete,  leading to  a  statistical  distribution  of  “subunit
defects” within the 24-meric structure (Kim et al., 2011). Nonetheless, the pH
jump  method  is  still  the  most  popular  procedure  in  order  to  achieve
successful encapsulation. 
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Covalent Modifications
The covalent conjugation of drugs to proteins is a common method of drug-
loading  in  protein  carriers,  and  has  shown  its  potential  with  the  use  of
antibody-drug  conjugates  (ADC)  in  clinics.  The  added  value  of  using  a
protein cage is  the protected environment  it  offers,  useful  for  particularly
sensitive  drugs,  and  the  possibility  to  combine  multiple  strategies.  The
bioconjugation  of  small  molecules  to  aminoacid  side-chains,  native  or
recombinantly  engineered,  such  as  cysteines,  tyrosines,  or  the  amine  or
carboxyl groups, can be attained using a wide range of chemical techniques.
The approach for bioconjugation has to be carefully designed as it may result
in  poor  yields  and protein  instability.  (Molino  & Wang,  2014)  In  a  very
recent report, a successful conjugation of aldoxorubicin (doxorrubin with and
extra acid sensitive linker) with human ferritin external cysteine has been
obtained. However, further covalent modification with polyethylene glycol
molecules was necessary (Huang et al., 2017).
Pore Entry
 Even though the protein shell offers a protected environment for its cargo,
the  24-meric  scaffold  does  show  diverse  possible  pathways  for  small
molecules  entry/exit.  The eight  hydrophilic  channels  located  at  the  3-fold
symmetry  axis  display  a  relatively  broad  selectivity  and  allow  for  the
exchange  of  cations  during  mineralization/demineralization,  with  a
preference for divalent  cations  (Haikarainen et  al.,  2011).  They have also
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been proposed as the main route of entry for a number of other substances,
such as hydrophilic drugs and labeling fluorophores  (He & Marles-Wright,
2015; Wu et al., 2008). The remaining hydrophobic channels, located at the
four-fold axis can serve as entry for hydrophobic drugs and are thought to
work as proton outlets (Douglas & Ripoll, 1998). Besides the small four-fold
or three-fold channels, the overall intersubunit interfaces might offer room
for exchange of small molecules, as proposed very recently by Zhang et al
(2017). in a remarkable set of high resolution microscopy observations, they
have demonstrated that the ferritin shell is not entirely rigid, but does possess
a degree of flexibility, possibly due to a collective “breathing” motion that
involves dynamic readjustments of the subunits within the 24-mer. During
these motions, large organic compounds like curcumin and doxorubicin can
be  incorporated  within  the  cavity  simply  driven  by  the  outward/inward
concentration gradient. Thus, under appropriately high concentration of the
payload,  a  sufficient  incorporation can be achieved simply by mixing the
small  molecule  with  the  protein even at  neutral  pH values  (Zhang et  al.,
2017).
Physical Interactions
Although secondary, tertiary and quaternary structures of ferritins are well
conserved,  their  DNA sequences  can  have  low  homology.  (Harrison  &
Arosio, 1996) Nevertheless, apo-ferritin, i.e., when there is no formed iron-
core,  ferritins’  cavity  is  most  likely  filled  with  the  solvent  from  the
surrounding solution.  (Theil et al., 2006; Yang & Chasteen, 1996) Its inner
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surface  can  be  redesigned  to  improve  the  biding  of  cargo  molecules  by
genetically  engineering  residues  to  turn  the  cavity  more
hydrophobic/hydrophilic or by addition of specific binding sequences (Falvo
et al., 2016; Kitagawa et al., 2012).
Drug-release strategies
There are as many different ways to encapsulate probes as there are to release
them. The selection of the release mechanism is dependent on the desired
application and on the stability and chemical properties of the probe-cage
system. Engineering of this properties can be done in a similar fashion as for
probe-encapsulation. Using non-specific interactions for encapsulation results
in slow release of the probe over time. Controlled release can be achieved by
interfering with release kinetics, as for example: amide or thioether bonds are
disrupted during biodegradation  (Kang et al., 2012). Disulfide bonds allow
probe release in reducing environments and hydrazone bonds enable release
in slightly acidic conditions. These mimic conditions reported to occur during
endocytosis  (Molino & Wang, 2014).  In particular, it is expected that most
payloads  can  be  delivered  once  the  protein  is  confined  within  a  low pH
environment  in  lysosomes.  However,  given  the  complex  intracellular
pathway of ferritins, these expectations are not always fulfilled.
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1.2.2 Uptake and delivery mechanisms
Ferritin is responsible for iron storage within cells, however it also circulates
and has been demonstrated to bind specifically to diverse cell types. In the
1960’s several research groups reported the selected uptake of human ferritin
by tumor cells  (Easty et  al.,  1964; Ryser et  al.,  1962), and later, in 1988,
Fargion et al. Demonstrated human H-chain ferritin’s (HuHF) ability to bind
a 100 kDa protein (Fargion et al., 1988), however it was not until 2010 that
Li et al.  identified human transferrin receptor-1 (TfR1) as mediator of the
binding of HuHF, but not human L-chain ferritin (HuLF), to a variety of cell
types. (Li et al., 2010). Later on, Fan et al. reported that HuHF targets TfR1
on tumor cells and tissues obtained from clinical samples, including nine of
the  most  common  solid  tumors  –  liver,  lung,  colon,  cervical,  ovarian,
prostate, breast and thymus cancers (Fan et al., 2012). This dual capacity of
the  receptor  to  interact  with  both  transferrin  (Tf)  and  ferritin  raised  the
possibility that TfR1 acts a potential regulation center for the processing and
use of cellular iron storages.
Tfr1 is a homodimeric type II transmembrane receptor located on the cell
surface  that  has  been  identified  as  the  receptor  for  Tf,  essential  for  iron
delivery from Tf to cells. Each polypeptide subunit has approximately 760
aminoacids and is composed of a short N-terminal cytoplasmic domain,  a
hydrophobic transmembrane domain and a large,  globular  extracellular  C-
terminal domain with the binding site for transferrin (Lawrence et al., 1999).
TfR1 is thus established as a gatekeeper for the regulation of Tf-TfR1 iron
uptake pathway, the main route for cellular iron uptake. Additionally, TfR1
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has been shown to take part in the regulation of cell growth  (Aisen, 2004;
Neckers & Trepel, 1986) and multiple studies report an upregulation of TfR1
expression in proliferating cells, such as cancer cells  (Calzolari et al., 2007;
Kondo et al., 1990; Prutki et al., 2006; Ryschich et al., 2004). Overexpression
might be a consequence of the high rate metabolism of cancer cells resulting
in increased iron requirements since iron acts as an important co-factor for
enzymes involved in DNA synthesis (Daniels et al., 2006). Although TfR1 is
also present in normal physiological conditions, the overexpression of TfR1
in  cancer  cells  and its  efficient  internalization  highlight  its  potential  as  a
pharmacological target for cancer diagnosis and treatment.(Fan et al., 2013)
The  cellular  uptake  of  iron  via  the  TfR1  occurs  via  clathrin-mediated
endocytosis. Upon Tf binding to TfR1, two distinct pathways are described.
Either  the  complex is  recycled  back to  the  cell  surface  or  it  proceeds  to
lysosomal degradation (Figure 1.2).
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A considerable amount of effort has been dedicated to the development of
strategies targeting TfR1 for cancer diagnosis and treatment. One of the most
extensively studied systems concerns the doxorubicin-transferrin conjugate
(Munns et al., 1998; Tortorella et al., 2014). Doxorubicin is widely used in
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Figure 1.2 – Transferrin receptor-mediated endocytosis. Upon binding, endocytosis
begins with the formation of clathrin-coated pits, and migration of the complex to
the cytoplasm. Transferrin then enters the endosomes where dissociation of iron
from transferrin occurs. At this point, one of two routes can be taken: either the
complex is  recycled back to  the  surface or undergo lysosomal  degradation.  The
majority (85-95%) of the receptors will be recycled and a small fraction (5-15%)
will be follow the degradation pathway for the purpose of receptor turnover. Image
adapted from Tortorella et al. (Tortorella et al., 2014)
the  treatment  of  a  large  variety  of  cancers  but  despite  its  large  spectrum
applicability to treat malignancies, its use is dose-limited as it accumulates in
cardiac tissue, causing significant cardiotoxicity  (Carvalho et al., 2009). By
directing  doxorubicin  to  cancer  cells,  one  can  reduce  its  accumulation  in
heart and improve the concentration of drug in the tumor tissue.
Another noteworthy strategy using TfR1 targeting is the use of transferrin
/anti-transferrin  receptor  antibodies  for  delivery of  therapeutics  across  the
blood brain barrier. Crossing the blood brain barrier is a major limitation in
the treatment of many brain conditions as many free drugs do not have the
necessary  characteristic  to  cross  it.  Transferrin/anti-transferrin  receptor
antibodies complexes have demonstrated to cross the blood brain barrier and
modified versions of it might be developed as carriers for brain therapeutics.
(Burdo & Connor, 2003; Dufes et al., 2013).
The demonstration that HuHF binds to cells through the TfR1, puts ferritin
on the spotlight for the development of next generation cancer therapeutics.
The ferritin’s natural tropism to TfR1 can be exploited to design molecular
trojan horses against cancer. Upon binding, HuHF follows a similar pathway
to that of Tf. It  undergoes endocytosis and is directed to endossomes and
lysosomes, where it is able to release its iron content in sufficient quantities
to alter the gene expression dependent of iron. Further studies defining the
fate of HuHF after it reaches the lysosome will help to develop strategies for
controlled cargo delivery (Li et al., 2010). Nevertheless, it is now clear that
when ferritin  is  uptaken and internalized  by  TfR1,  the  complex does  not
necessarily follows the typical pathway sketched in Figure 1.2 and further
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branching  of  the  intracellular  pathway  have  been  proposed,  including
targeting to the nucleus (Alkhateeb & Connor, 2010; Surguladze et al., 2005;
Thompson et al., 2002).
Other than TfR1, other receptors have been fount to bind ferritin. Li et al
found  that  mouse  scavenger  receptor  class  A  member  5  (Scara5)  was
responsible for binding and endocytosis of serum ferritin, in mice.  Scara5
binds preferentially to murine L-ferritin,  and it  plays an important role in
kidney organogenesis  (Li et al., 2009).  Han et al describe the specific and
saturable binding of ferritin to T cell immunoglobuline and mucin domain
containing receptor 2 (TIM-2), on mice  (Han et al., 2011). TIM-2 has been
found to be overexpressed in oligodendrocytes. These cells have increased
iron needs for the production of mielin and authors hypothesized that TIM-2
functions as an iron uptake mechanism (Todorich et al., 2008). However both
Scara5  and  TIM-2  receptors  are  not  expressed  in  humans,  and  lack  of
evidence that either murine or human ferritin bind to murine TfR1 suggests
that the underlying recognition mechanisms have diverged between humans
and mice (Han et al., 2011; Li et al., 2010).
The recent advances in understanding of the ferritin uptake and its fate in
many cellular models strongly reinforce the potential of using ferritin-based
DDS. In addition to the specific and selective binding to cancer cells, ferritin
nanoparticles  dimensions  are  ideal  to  tumor  targeting  through  enhanced
permeability and retention (EPR) effect, where the abnormal vascular growth
in tumors increases the likelihood of accumulation of nano-sized particles
(Lee et al., 2016).
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Collectively,  broad  knowledge  in  cancer  biology  and  promising  results
obtained in conjugation/encapsulation of cancer drugs with ferritin provide
rationale to pursue the development of ferritin-based therapies.
1.2.3 Other applications
Although ferritin has showed enormous potential as in vivo DDS for cancer.
However, the ferritin scaffold can be used for many other applications. In this
section  a  few  selected  examples  of  ferritin  used  in  biotechnology  are
described.
Industrial phosphate and arsenate removal from water
The use of  Pyrococcus furiosus ferritin for the removal of phosphates from
water is one of the very few industrial-scale uses of ferritin  (Jacobset al.,
2010). It has been developed as an industrial scale solution to prevent the
eutrophication of water as a consequence of excessive growth of algae and
aquatic plants whose limiting nutrient  is  inorganic phosphate.  The current
available  methods  for  phosphate  removal  rely  on  the  precipitation  of
phosphate using calcium and aluminum sulfates or biological methods where
bacteria are used to sequester calcium. Later on, Sevcenco et al. expanded
this  approach  to  the  removal  of  arsenate  from  water,  a  problem  taking
considerable proportions in India and Bangladesh  (Sevcenco et  al.,  2015).
Ferritin has the the ability to sequester phosphate and arsenate through the
iron oxides and hydroxides within its core. The adsorption of phosphates and
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arsenate can occur either concurrently with the iron core formation or after its
completion.  P.  furiosus ferritin  seems specially  adequate  for  this  purpose
since it  can be  easily  and abundantly  expressed recombinantly,  making it
suitable for large-scale production,  and since it  is  endowed of remarkable
thermostability  due  to  the  fact  that  it  is  isolated  from  a  thermophilic
organism. This approach shows great potential to reduce costs, nevertheless
its wide spread applicability still remains to be assessed (Jacobs et al., 2010).
Ferritin for medical imaging
Ferritin has shown to be and ideal tool for cellular imaging, as labeled heavy
atoms can be readily sequestered within its core. Furthermore, iron loaded
ferritin has been used as contrast agent in both electron microscopy and MRI.
Ferritin  fulfills  the  requirement  of  a  good  cellular  label  for  electron
cryotomography (cryo-ET) since its iron core provides significantly higher
contrast than the cellular background. Moreover, inclusion of a fluorescent
moiety in the ferritin allows to combine fluorescence microscopy and cryo-
transmission electron microscopy (cryo-TEM) imaging techniques  (Wang et
al., 2011). For MRI, a powerful tool in both clinical and research context, the
superparamagnetic properties of the iron oxides and hydroxides found in the
ferritin core provide the necessary dark contrast in MRI images. Endothelial
tumor cells were visualized by MRI using recombinant gadolinium-loaded
ferritin bearing a peptide targeting a protein whose expression is limited to
cancer cells (Geninatti Crich et al., 2015). This strategy can be extended for
imaging of a many other targets simply by changing the moiety responsible
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for  the  targeting.  Ferritin-based  imaging  probes  recall  the  properties  of
liposomes  and  other  vesicle-like  system,  with  the  advantage  of  having  a
smaller  size  which  improves  its  accessibility  to  targets  outside  the
bloodstream. 
Ferritin as biomineralization template
The use of biomolecules for the synthesis of inorganic nanomaterials is an
emerging  trend.  Biological  systems  are  unique  in  their  versatility  and
nanoparticle  size,  shape,  morphology,  can  be  controlled  by  modifying
interaction  between  inorganic  materials  and  biomolecules.  Moreover,
biotemplate-directed synthesis can be more “green” than traditional chemical
reactions as they usually require less harsh conditions of pH and temperature
and use less often organic solvents.
By taking advantage of the physiological role of ferritin to store iron in the
form of a ferrihydride core, many have employed ferritin as size-constrained
reaction environment for the synthesis of different types of nanoparticles –
metals, oxides, hydroxides, carbonates, semiconductors. For example, Fan et
al.  have  described  a  new  two-step  method  for  the  synthesis  of  gold
nanoparticles in horse spleen ferritin (HoSP),  using the natural negatively
charged  character  of  ferritin’s  cavity  to  form  clusters  than  nucleate
nanoparticle growth within the protein shell (Fan et al., 2010).
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Ferritin in vaccine design 
The  structural  resemblance  of  ferritins  to  viral  capsids  makes  them  an
attractive target for vaccine development. An elegant example is the work
carried  by  Kanekiyo  et  al.,  where  the  protein  heamagglutinin  (HA) from
influenza virus was fused to the surface of Helicobacter pylori ferritin. These
decorated ferritins were able to elicit the production of broadly neutralizing
antibodies  with  enhanced  potency  when  compared  to  a  commercially
available  vaccine.  The  use  of  synthetic  nanoparticle  vaccines,  entirely
recombinantly produced, could eliminate the need to work with live viruses
in culture, reducing both risks and costs (Kanekiyo et al., 2013).
1.3 Assembly of protein cages
Proteins are often referred as building blocks, puzzle pieces or LEGO bricks.
These analogies refer to the modular nature of proteins, whose functions are
tightly related to their  structure.  Nature,  similarly to engineering,  tends to
combine smaller parts, or modules, to construct larger, more complex objects:
nature reuses instead of reinventing.  Biological  systems use modularity at
many  levels,  ranging  from  the  molecular  level  up  to  the  formation  of
complete organisms (Daviset al., 2002). A striking example is provided at the
levels of organization of protein structure: at the primary level, by combining
the same basic twenty-one aminoacids in different ways, one obtains defined
secondary structures such as α-helices and β-sheets, which in turn organize in
specific tertiary level structural domains such as zinc-finger domains, four-
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helix bundles or globin folds. To sum up, from the same basic blocks it is
possible to make virtually all the proteins necessary for function and thriving
of  life.  Moreover,  in  multidomain  proteins,  smaller  domains  with varying
sizes and functions are joined in different combination to achieve different
functions.  Development  of  “modules”  simplifies  and  accelerates  the
evolution of biological entities (Moore et al., 2008). Despite the usefulness of
the  LEGO  analogy  in  explaining  a  complicated  molecular  process,  it  is
important  to  state  that  it  is  an  over  simplification  of  the  complexity  of
proteins  three-dimensional  structure,  overlooking  fundamental  properties
such as the plasticity,  softness and dynamics that are essential  for protein
function (Levy, 2017).
Protein cages can be seen as a combination of smaller modules having a self-
assembly behavior which permits the encapsulation of a variety of cargoes.
These modules can be chemically and genetically modified giving them new,
unique  properties  (Maassen et  al.,  2016).  Protein  assembly  comprises  the
formation  of  secondary,  tertiary,  quaternary  and  supramolecular  structure.
Nevertheless, when considering protein-cages, self-assembly usually refers to
formation of quaternary structure and the understanding of the fundamental
biochemical and biophysical processes governing protein-cage self-assemble
is essential for the design of tailored cages for a wide range of purposes.
Self-assembly of proteins in complexes has a crucial role in biology. Some
complexes  self-assemble  by  design,  such  as  naturally  occurring  protein
cages. Others assemble as an unwanted consequence, as in the case of the
amyloid  β-protein  aggregation  found  in  Alzheimer’s  disease  (Hardy  &
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Selkoe,  2002),  or  the  single-point  mutation  of  hemoglobin  causing  its
polymerization  and  underlying  the  pathogenesis  of  sickle  cell  anemia
(Noguchi & Schechter, 1981).
In  recent  decades,  with  the  arising  of  better  and  faster  methods  for
determination of protein atomic structure, much has been improved in the
understanding of the principles of quaternary structure assembly. Such that
our conception of protein complexes has shifted from static representations to
representations where dynamic aspects of quaternary structure are accounted
for,  including  conformational  changes  upon  binding,  multistep  ordered
assembly  pathways,  and  structural  fluctuations  occurring  within  fully
assembled complexes (Marsh & Teichmann, 2015).
For any protein complex with more than two subunits, assembly becomes
more and more complex as it is no longer a simple binary interaction. An
analogy  can  be  drawn from Levinthal’s  folding  paradox  (Zwanzig  et  al.,
1992) – if a protein were to attain its folded state by sequentially sampling all
the possible conformations, it would require an enormously long time, yet
most proteins fold in the micro to millisecond time scale – whereby complex
formation  is  likely  to  occur  via  an  energetically  favorable  pathway,  or,
similarly  to  what  has  been  proposed  for  protein  folding,  via  multiple
pathways exploring a funnel-like energy landscape (Dill & Chan, 1997).
Protein-cages can be described as particular case of homomeric (for most
cases, assembly units can be simplified to a homomer) protein complexes,
arranged  with  a  high  degree  of  symmetry  in  a  spherical  macro-structure.
These can generally be classified as belonging to tetrahedral, octahedral, or
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icosahedral  symmetry  group.  Tetrahedral  homomers  have  twelve  subunits
with  two-fold  and  three-fold  symmetry  axes.  Octahedral  homomers  have
twenty-four subunits with two-fold, three-fold, and four-fold symmetry axes.
Icosahedral  complexes  have  sixty  subunits  with  two-fold,  three-fold,  and
five-fold symmetry axes (Marsh & Teichmann, 2015).
Much  has  been  done  in  the  study  of  self-assembly  of  protein  cages.
Specifically  viral  capsids,  since  its  self-assembly  can  be  triggered  upon
mixing monomers with nucleic acid, which makes them ideal model systems.
Experiments  and  simulations  have  shown  that  capsid  assembly  can  be
divided in two phases: nucleation and growth. In nucleation a critical nucleus
– smallest intermediate that has more than 50% probability of growing into a
complete  capsid  before  disassembling  – is  formed,  followed by a  growth
phase  where  remaining  subunits  are  added  sequentially  (Prevelige  et  al.,
1993).  For  both  processes  the  loss  of  translational  entropy  during  self-
assembly is balanced by gains from specific hydrophobic, electrostatic, van
der Waals, and hydrogen-bonding interactions  (Perlmutter & Hagan, 2015).
Smaller intermediates are unstable and transient formation of critical nucleus
is a rare event, while in the growth phase intermediates are relatively stable
and addition of subunits is independent, thus the timescale to achieve full
assembly  has  a  low  order  dependence  on  the  free  subunit  concentration
(Hagan & Elrad, 2010). Due to the geometry of the protein shell, the first few
intermediates have relatively few subunit-subunit contacts and are relatively
unstable. The critical nucleus geometry maximizes the number of interactions
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and often corresponds to a small polygon and subunit conformation changes
may provide additional stabilization upon polygon formation (Hagan, 2014).
Although many experiments have provided vast information on the kinetics
of  capsid  assembly,  detailed  characterization  of  pathways  remains
challenging since intermediates a unstable and short lived  (Zlotnick et al.,
1999). Some inventive approaches have been investigated, such as the works
carried by Zhou et  al.  where restive pulse sensing was used to probe the
passage of Hepatitis B virus (HBV) capsids through conical nanopores in a
membrane  and  successfully  distinguished  between  two  different  final
assembled states (Zhou et al., 2011).
Upon  assembly,  capsid  can  undergo  maturation,  which  involves
conformational  rearrangements or even covalent modifications that mostly
increase the stability of the final assembled particle. Nevertheless, it remains
a  dynamic  structure  able  to  undergo  conformational  changes  required  to
attain its intended biological function (Mateu, 2013).
1.3.1 The ferritin self-assembly 
The  self-assembly  mechanism  of  protein  supramolecular  complexes  is  a
challenging subject especially if the structures are highly symmetrical and
homo-oligomeric. In general, the characterization of thermodynamically and
kinetically  accessible  intermediates  for  the  association  and  disassembly
pathways  can  be  considered  as  a  pre-requisite  in  order  to  achieve  a
mechanistic insight. In practice, these studies are complex due to difficulties
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with  the  determination  of  folding  and  assembly  rate-limiting  steps  and
coupling between the two. Inspection of the threedimensional structures of
ferritins  suggests  that  stable  dimers  are  the  most  likely  candidates  as
assembly intermediates due to the extensive intersubunit contacts that suggest
higher interaction energies with respect to other  oligomers.  Sedimentation
velocity analytical ultracentrifugation on horse heart ferritin as a function of
pH not only demonstrated the stability of dimers in HoSF  (Stefanini et al.,
1987) but also suggested that assembly entails the formation of other discrete
oligomeric species such as tetramers and octamers. Other investigations on
homomeric  H  type  ferritins  confirmed  that  the  dimer  is  the  most  highly
populated species but suggested that other discrete species such as hexamers,
in  small  amounts,  and  dodecamers  are  also  formed  during  the  assembly
pathway (Sato et al., 2015). These results led to a refined model where the
24-meric cage assembles from dimer via tetramers and hexamers. Recently, a
complete  quantitative data  analysis  of  SAXS measurements  indicated that
apoferritin  can  undergo  stepwise  disassembly  through  several  structural
intermediates  below pH 3.40  (Kim et  al.,  2011).  The dissociation process
starts  with  hollow  spherical  structures  with  two  holes,  followed  by
“headphone”-shaped  structures,  and  lastly  rod-like  oligomers  (mainly
trimers) or monomers. The structural recovery of the intermediates during the
pH-induced reassembly process was proposed to be dependent on the history
of the disassembly process, and that hole defect (22-mers or 23-mers) could
never  be  recovered  back  to  the  intact  24-mers.  How  this  data  relates  to
proposed mechanisms of assembly has yet to be explored  (Zhang & Orner,
2011).
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1.4 Future prospects
The  current  research  on  ferritin  assembly  mechanism  and  its
nanotechnological and biotechnological applications is currently exploding as
witnessed  by  the  increasing  number  of  experimental  and  theoretical
observation  published  recently.  Major  efforts  are  devoted  to  the
understanding of the physical basis of the complex assembly mechanism on
one side, and on the growing attempts to set up a more efficient scaffold for
payload  encapsulation  on  the  other.  The  key  advantage  of  ferritins  as
nanocarriers over other systems are well known: uniform and homogeneous
size  distribution  of  the  nanoparticle,  easy  manufacturing  procedure,
unmatched  overall  thermodynamic  stability  and  easy  functionalization  on
both the internal and external surfaces. Under these premises, it is envisaged
that  ferritin  based  technologies  will  rapidly  expand  in  wide
nanotechnological  applications  in  many  diverse  fields,  spanning  from
biomedicine  to  nanoengineering,  nanochemistry  and  smart  materials.  The
biomedical  applications,  in  particular,  are  gaining  enormous  popularity  in
view of the unique property of ferritin based nanocarriers, i.e., the targeting
capability to the TfR1 receptor, a key target for tumor delivery.  However,
many reports have already pointed out that ferritins might also be engineered
to  carry  alternate  epitopes  for  the  recognition  of  specific  cell  surface
receptors other that TfR1. Such versatility will possibly expand the scope of
therapeutic application thus transforming ferritins in universal, broad range
scaffolds  for  cellular  targeting.  As a  last  mention,  one may infer  that  the
34 
advantage  of  having the  possibility  of  24  epitopes  on  the  same molecule
would greatly enhance the possibility of having stronger interactions with the
desired targets even over antibodies. Research efforts in this sense are only at
the early stage, but promise a revolution in drug delivery in the near future.
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2 Aim of the work
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The work presented in this thesis aimed to set out the basis for the rational
design  of  innovative  protein-based  carriers  for  drug-delivery  and
biotechnological applications. In this context, ferritin stood out as promising
protein system due to  its  remarkable characteristics.  Ferritins are  versatile
biocompatible  proteins  scaffolds  that  display  a  cage-like  structure  that
provides shielding of the cavity’s content from harsh external conditions, and
are amenable to modifications in a relatively straightforward manner.
Previously  published  information  suggested  that  ferritins  cages  present  a
unexpected degree of plasticity in that they are able to undergo significant
structural rearrangements in order to host small molecules within the internal
cavity, a process referred to as “encapsulation”. However, in order to clarify
the  process  of  molecule  confinement  within  ferritin  the  internal  cavity,  a
critical  analysis  of  the process of  ligand entry/release through the protein
matrices of ferritins of diverse origin was deemed necessary.
The current project thus focuses on the design of ferritin-based nanocarriers,
that  exploit  the  convenient  properties  of  archaeal  ferritins.  These  proteins
displays unique assembly properties and extreme thermodynamic stability,
however  lack  the  cell  recognition  properties  of  human  ferritin.  Thus  we
designed a chimeric protein in which the relevant recognition sequence of
human ferritin  was  grafted  into  the  corresponding  sequence  into  archaeal
ferritins surface exposed regions in order to confer specific recognition of
human  epitopes.  The  development  of  such  innovative  ferritins  nanocages
aimed to generate universally applicable ferritin nanocarriers for biomedical
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and  biotechnological  purposes.  The  assembly  properties  of  the  novel
archaeal-human chimeric ferritin nanocarrier was extensively investigated in
this work with the aim of greatly improving the current methods of probe
encapsulation within ferritins. These studies can thud provide key elements
for the development of strategies for efficient encapsulation/release of probes
in a controlled way.
On a different approach, this work aimed to exploit the versatility of ferritins
for  bioimaging  applications,  by  inserting  an  extra  functional  segment  for
binding  of  luminescent  lanthanides,  within  a  mammalian  ferritin’s  cavity.
These systems could be used for advanced cell imaging applications, merging
the  recognition  capabilities  of  ferritins  with  the  notable  properties  of
lanthanide-based fluorescence.
38 
3 Materials and methods
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3.1 Archaeal ferritin’s permeation properties
Point mutations and protein expression
The genes encoding for bacterial ferritin from A. fulgidus ferritin (AfFt) and
P. furiosus ferritin  (PfFt)  were  cloned into  the  expression  vector  pET22b
(Novagen).  Point  mutants  AfFt-M54C,  AfFt-M54C/K150A/R151A,  PfFt-
G52C and PfFt-P77C were obtained by polymerase  chain reaction  (PCR)
using QuickChange Mutagenesis kit (Stratagene). The recombinant plasmids
were transformed into  E. coli  TOP 10 cells and the resulting colonies were
screened by DNA sequencing. Plasmids bearing the desired mutations were
transformed into BL21(DE3)  E. coli strain for protein expression. For each
mutant, protein over-expression was obtained as it follows: 1 L Luria-Bertani
(LB) broth medium was inoculated with 2 mL overnight culture of a single
colony and the gene expression was induced with 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) when the absorbance at 600 nm reached 0.6.
Cells were harvested by centrifugation after overnight induction at 37 °C and
the cell pellets were stored at -20 °C.
Protein purification
Harvested  cells  from  1  L culture  over-expressing  AfFt-M54C  and  AfFt-
M54C/K150A/R151A mutants were resuspended in 20 ml buffer (20 mM
HEPES pH 7.4,  300  mM NaCl)  containing  a  cOmplete™ Mini  Protease
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Inhibitor Cocktail Tablet (Roche) and disrupted by sonication. The soluble
fraction was thermally purified by heating at 85 °C for 10 minutes followed
by removal  of  denatured  proteins  by  centrifugation  at  11000 rpm for  30
minutes  at  4  °C.  The  supernatant  was  fractioned  by  ammonium  sulfate
precipitation.  70%  ammonium  sulfate  pellet  containing  highly  purified
protein was resuspended in 20 mM HEPES pH 7.4, 20 mM MgCl2, dialyzed
versus  the  same  buffer,  sterile  filtered  and  stored  at  4  °C.  Cells  over-
expressing  PfFt-G52C and  PfFt-P77C were  sonicated  in  20  mM HEPES
buffer  at  pH  7.4,  0.3  M  NaCl  and  cOmplete™  Mini  Protease  Inhibitor
Cocktail  Tablet.  After  sonication,  the  crude  bacterial  extract  was  digested
with DNase for 1 hour at 37 °C, heated at 80 °C for 10 minutes followed by
centrifugation  to  remove  insoluble  material.  Then,  the  supernatant  was
further purified by ammonium sulfate precipitation. 70% ammonium sulfate
pellet was resuspended in 20 mM HEPES pH 7.5, 150 mM NaCl, dialyzed
versus the same buffer and loaded onto a HiLoad 26/600 Superdex 200 pg
column (GE Healthcare). Fractions containing highly purified protein were
pooled, sterile filtered and store at 4°C.
Preparation of ferritin-DTNB adducts
All mutants were reduced with 3 mM tris(2-carboxyethyl)phosphine (TCEP)
in  their  storage  buffers  and  then  loaded  onto  a  desalting  column  (GE
Healthcare) to remove the reducing agent. Each mutant was reacted with 40-
fold molar excess of Ellman’s Reagent, 5.5’-dithio-bis-(2-nitrobenzoic acid)
(DTNB) per cysteine for 3 hours at room temperature. Stock DTNB solutions
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were prepared in ethanol. The excess (non-reacted) reagent was removed by
ultra-filtration using 100 kDa Amicon Ultra-15 centrifugal devices (Millipore
Corporate).
Stopped flow experiments
Kinetic  measurements  were  carried  out  on  a  thermostated  Applied
Photophysics stopped-flow apparatus (Leatherhead, UK) by mixing 8-10 μM
protein solutions, previously reduced with TCEP, with solutions containing
different concentrations of DTNB (from 0.2 to 0.7 mM after mixing) in 20
mM HEPES, 20 mM MgCl2 pH 7.5. In order to avoid interference of the
instrument phototube from the high concentrations of DTNB and the released
chromophore 5-thio-2-nitro-benzoic acid (TNB), the reaction was followed at
430 nm and the extinction coefficient calculated to be 12205 mM-1cm-1, as
determined from the extinction coefficient  of  14150 mM-1cm-1 at  412 nm
(Riddles et al., 1979). All fitting procedures were carried out by using Matlab
software (Mathworks, USA). Experimental traces were fitted by non-linear
regression  to  either  exponential  or  biexponential  processes  by  using  an
Levenberg-Marquardt algorithm.
Self-assembly study
MgCl2 mediated  self-assembly  of  ferritin  mutants  was  confirmed  by
incubating aliquots of proteins (1 mg/ml) with different salt concentrations in
20 mM HEPES buffer, pH 7.4. Molecular sizes of AfFt-M54C, AfFt-M54C/
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K150A/R151A,  PfFt-G52C  and  PfFt-P77C  were  determined  by  size
exclusion  chromatography  (SEC)  using  HiPrep  16/60  Sephacryl  S300
column (GE Healthcare). The column was equilibrated with 20 mM HEPES
pH 7.4, 20 mM MgCl2. Molecular weight of each mutant were determined by
comparing  their  elution  volumes  with  the  elution  volumes  of  standard
proteins at the same salt concentration.
Liquid Chromatography – Mass Spectrometry
Liquid Chromatography – Mass Spectrometry (LC–MS) was performed on
protein samples before and after DTNB titration, after  dialysis in distilled
water in the presence of 0.1 mM ethylenediaminetetraacetic acid (EDTA),
using  a  Waters  AcquityuPLC  connected  to  Waters  Acquity  Single  Quad
Detector. A Hypersil Gold C4 column was used: 1.9 μm, 2.1 × 50 mm at 254
nm  observation  wavelength;  mobile  phase:  95:5  water  (0.1%  formic
acid):MeCN (0.1% formic acid); gradient over 6 min (to 5:75 water (0.1%
formic acid):MeCN (0.1% formic acid); flow rate: 0.4 ml min−1; MS mode
was set at a scan range: m/z=250–2,000 (ES+); scan time: 0.25 s. Data were
obtained in continuum mode by setting the electrospray source of the MS
with a capillary voltage of 3.5 kV and a cone voltage of 50 V. N2 gas was
used as nebulizer and desolvation gas at a total flow of 300 l/hours. Ion series
were generated by integration of the UV signal at  254 nm chromatogram
over 1.2–1.8 min range. Mass spectra were subsequently reconstructed for
proteins  from the ion series  using the MaxEnt 1 algorithm on MassLynx
software program.
43 
3.2 Humanized archaeal ferritin
“Humanized” Archaeoglobus ferritin design
The gene encoding for a mutated ferritin from A. fulgidus was synthesized by
GeneArt (ThermoFisher)  and sub-cloned into a  pET22b vector  (Novagen)
between the restriction sites NdeI and HindIII at 5′ and 3′ respectively. The
recombinant  plasmid  was  transformed  into  BL21(DE3)  E.  coli strain  for
protein expression.
Protein expression and purification
E.  coli cells,  containing  the  Humanized  A.  fulgidus ferritin  (HumAfFt)
plasmid, were grown and induced with 1 mM IPTG at OD600 = 0.6. Cells
were harvested by centrifugation 18 hours  post  induction at  37 °C.  Cells
harvested from 1 L culture were resuspended in 20 mM HEPES buffer, pH
7.4, containing 300 mM NaCl,  and a cOmplete™ Mini Protease Inhibitor
Cocktail Tablet (Roche). Cells were disrupted by sonication and the soluble
fraction was purified by heat treatment at 80 °C for 10 minutes. Denatured E.
coli proteins were removed by centrifugation at 11000 rpm at 4 °C for 30
min.  The  soluble  protein  was  further  purified  by  ammonium  sulfate
precipitation.  The  precipitated  fraction  at  70%  ammonium  sulfate  was
resuspended in 20 mM HEPES, 50 mM MgCl2, pH 7.4 and dialyzed versus
the same buffer. As a final purification step, the protein was loaded onto a
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HiLoad 26/600 Superdex 200 pg column previously equilibrated in the same
buffer using an ÄKTA-Prime system (GE Healthcare). The purified protein
was  concentrated  to  obtain  the  final  protein  preparation  and  protein
concentration were routinely calculated by measuring the UV spectrum using
an extinction coefficient of 32400 M−1 cm−1.
Self-assembly assessment in solution
SEC  MgCl2-mediated  self-assembly  was  studied  using  a  Superdex  200
26/600 GL column (GE Healthcare). The molecular size of HumAfFt was
determined under different conditions by comparing the elution volume with
that  of  standard  proteins.  Composition  of  the  mobile  phase  was  20  mM
HEPES  pH  7.4  with  different  MgCl2 concentrations  accordingly  to  the
experiment requirements.
Crystallization and crystal structure determination
The  purified  protein  was  concentrated  to  20  mg  mL−1 and  initial
crystallization screening was performed using a Phenix Robot. Crystals were
obtained by mixing in a 2 μL hanging drop of the purified protein with a
solution containing 22% (vol/vol) polyacrylic acid (PAA), 0.1 M Tris, 0.02 M
MgCl2,  pH 7.4,  at  25 °C within a week, cryo-protected by increasing the
precipitant  concentration  and flash-frozen  in  liquid  nitrogen for  transport.
Diffraction  data  have  been collected  at  ID23-2 beamline  at  the  European
Synchrotron  Radiation  Facility  (ESRF),  Grenoble,  France.  Data  were
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processed with XDS (Kabsch, 2010) and scaled with Aimless (ccp4 suite) at
a  final  resolution  of  2.87  Å.  The  structure  was  solved  by  Molecular
Replacement with MolRep (ccp4 suite)  using the wild type structure AfFt
(PDB code 1S3Q) as the search model  (Winn et al., 2011). Model Building
and  refinement  were  done  using  Coot  (Emsley  &  Cowtan,  2004) and
Refmac5  (Murshudov  et  al.,  2011a),  respectively.  The  final  model  was
analyzed with PROCHECK (Laskowski e al., 1993) and Molprobity (Chen et
al.,  2010).  The Ramachandran plot  showed that  97.8% of  residues  are  in
preferred regions, 2.2% in allowed regions and no outlier is observed. The
final atomic coordinates and structure factors were deposited with the PDB
Data Bank (http://www.rcsb.org) with accession code: 5LS9. 
Cryo-Electron microscopy
Holey-gold  grids  were  prepared  as  described  before  (Russo  & Passmore,
2014) from Quantifoil R1.2/1.3 (Quantifoil Micro Tools GmbH, Germany). 3
μL of HumAfFt was applied to the holey-gold grids after plasma cleaning
with a mixture of H2 and O2. Grids were blotted for 4 seconds and vitrified by
rapidly  plunging  into  liquid  ethane  at  -180  °C  with  a  Vitrobot.  Data
acquisition was done using a FEI Titan Halo (FEI, Eindhoven) operating at
300 kV. Datasets were imaged with a Volta phase-plate (Danev et al.,, 2014)
(FEI,  Eindhoven)  and  were  collected  with  the  automated  data  collection
system EPU (FEI, Eindhoven) at a nominal magnification of 59000× on an
FEI  Ceta  camera  (FEI,  Eindhoven)  with  a  camera  pixel  size  of  14  μm,
corresponding to a calibrated pixel size of 1.49 Å on the specimen scale and
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with a dose of 50 e− Å−2. Images were processed with the reference-based
automated particle picking procedure implemented in RELION 1.3 (Scheres,
2012) . Contrast transfer function (CTF) correction was not applied since the
data were collected within 200 nm of focus and the first CTF zero crossing
was well  beyond the  achievable  resolution  of  the dataset.  Those particles
were subjected to  2D classification using RELION with k = 100 classes.
Good particles were then subjected to 3D classification using RELION with
the  number  of  classes  K  =  8.  Resulting  classes  were  refined  with  the
autorefine procedure in RELION. Reported resolution is based on the ‘gold-
standard’ protocol with the Fourier shell correlation (FSC) = 0.143 criterion
using soft masks with an 8 pixel soft edge, and were corrected for the effects
of the mask on the FSC curve using high-resolution noise substitution (Chen
et al., 2013).
Protein FITC labeling
HumAfFt,  AfFt  and  holo-transferrin  were  labeled  with  fluorescein-
isothiocyanide  (FITC)  according  to  the  manufacturer’s  standard  protocol.
Briefly,  2 mg mL−1 of  the purified protein was added with 10-fold molar
excess of in protein storage buffer stirring for 4 hours at room temperature.
The nonreacted dye was removed by gel filtration chromatography and the
fluorescent dye to protein ratio was determined by UV-spectroscopy. LC-MS
spectrometry  measurements  on  HumAfFt-FITC  confirmed  that  >60%  of
monomers are FITC labeled.
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Cell cultures and ferritin internalization
HeLa cells were grown at 37 °C in Eagle’s MEM supplemented with 10% (v/
v)  fetal  bovine  serum  (FBS),  Glutamax  (Invitrogen)  and  penicillin–
streptomycin solution (Sigma).  When needed, the cells  were induced with
doxycycline  0.2  µg  mL−1.  The  internalization  assay  was  performed  as  it
follows: after seeding the cells on the relevant substrate depending on the
experiment, cells were left one day to attach and then incubated with FITC-
ferritin nanoparticles (AfFt-FITC, HumAfFt-FITC or Tf-FITC as specified in
each  experiment)  at  the  final  concentration  of  30  µg  ml−1 for  the  time
indicated (1 h, 3 h or 20 h).
For evaluation of the TfR1 silencing effect on HumAfFt uptake by Hela cells,
cells  were  transfected  with  anti-TfR1  siRNA  (Sigma-Aldrich)  with
Lipofectamine®  RNAiMAX  (Life  Technologies)  following  standard
procedure.  Cells  were  then  incubated  with  30µg/ml  of  Hum  AfFt-FITC,
treated and analyzed as described in the methods session. The FITC intensity
was normalized for the FITC intensity of the scr samples.
Flow cytometry analysis
For flow cytometry analysis, or fluorescence activated cell sorting (FACS),
HeLa cells were seeded on multiwell plates. Cells were incubated with FITC-
ferritin nanoparticles as described previously, then washed two times with
phosphate-buffered saline (PBS), detached with trypsin-EDTA (Euroclone),
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washed with PBS and resuspended in BD-FACS flow buffer. Half of each
sample was treated with Trypan Blue (TB) to quench the FITC signal from
membrane-bound  nanoparticles  that  were  not  internalized.  The  quenching
was performed with 0.04% TB for 10 min, on ice. Control cells were treated
in  the  same  way  but  without  FITC-ferritin  incubation.  Internalization  of
ferritins  before  and  after  TB  treatments  was  measured  at  the  BD
LSFORTESSA (BD Biosciences, San Jose, CA, USA) equipped with a 488
nm laser and FACS Diva software (BD Biosciences version 6.1.3). Live cells
were first gated by forward and side scatter area (FSC-A and SSC-A) plots,
then detected in the green channel for FITC expression (530/30 nm filter) and
side scatter parameter. The gate for the final detection was set in the control
sample. Data were analyzed using FlowJo 9.3.4 software (Tree Star, Ashland,
OR, USA).
Confocal microscopy of live cells
To visualize ferritin internalization by live cells using a confocal microscope,
HeLa  TagRFP cells  were  seeded  on  a  μ-slide  8-well  ibiTreat  (ibidi)  and
induced with 0.2 µg mL−1 of doxycycline. Cells were then incubated with
FITC-ferritin nanoparticles as previously described, for 20 hours and, before
microscopy, cells were washed two times with an imaging medium (DMEM
without  phenol  red,  10% FBS,  10  mM Hepes,  Glutamax  and  penicillin–
streptomycin solution) to eliminate the unbound FITC-ferritin nanoparticles.
The  confocal  laser-scanning  microscope  used  was  an  Olympus  FV10i
platform equipped with a built-in  incubator.  Images were acquired with a
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60×/ 1.2NA water-immersion objective, LD lasers, 473 nm and 559 nm, and
filter sets for FITC.. Phase-contrast images were acquired simultaneously.
Dynamic Light Scattering 
Dynamic  Light  Scattering  (DLS)  experiments  were  carried  out  with  a
Zetasizer Nano S (Malvern Instruments, Malvern, U.K.) equipped with a 4
mW He-Ne laser (633 nm). Measurements were performed at 25 °C, at an
angle of 173° with respect to the incident beam. Peak intensity analyses were
used to determine the average hydrodynamic diameters (Z-average diameter)
of the scattering particles. All samples were prepared at 2 mg/mL in HEPES
20 mM pH=7.4 and filtered with a 0.2 µm filter before analysis.
Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) experiments were carried out using an
iTC200  microcalorimeter  (MicroCal).  HumAfFt  was  prepared  in  20  mM
HEPES pH 7.4 and an MgCl2 stock solution was prepared by dissolving the
powder into the same buffer solution to ensure buffer-matching between the
protein and the titrant. 1.5-μl aliquots of 4 mM MgCl2 were injected into a 15
μM protein solution at 25°C (each injection was time-spaced for 240 sec).
Data were fitted using a “one-binding-site model” of the MicroCal version of
ORIGIN.  The  heat  of  binding  (ΔH),  the  stoichiometry  (n),  and  the
dissociation constant (Kd) were then calculated from plots of the heat evolved
per mole of ligand injected versus the molar ratio of ligand to protein.
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Small Angle X-ray Scattering
Small Angle X-ray Scattering (SAXS) experiments were carried at the ESRF
at the ID02 and BM29 beamlines. X-ray wavelength was set at 0.99 Å (12.5
KeV) and temperature  kept  at  20 °C in  all  experiments.  two-dimensional
scattering images were obtained using Rayonix MX170-HS detector and a
1M Pilatus detector, for ID2 and BM29 respectively. Static measurements at
BM29 were  obtained  using  using  a  1.7  mm capillary,  while  flowing  the
sample,  with  0.5  seconds  exposure  time.  For  time-resolved  experiments,
sample was mixed using BioLogic SFM stopped-flow SFM400 apparatus,
equipped with a quartz cell of 1.4 mm diameter.
The self-assembly  reaction  of  HumAfFt  was triggered  by adding 20 mM
HEPES pH 7.4 with MgCl2 at various concentrations with a mixing ratio of
1:1. Time-resolved scattering data was obtained with 5 millisecond exposure
and an average  of  thirty  time-points  were  collected  per  mixing.  Reaction
time-course was obtained by combining different time-delays, and 10 to 15
mixings were averaged to increase signal to noise. For longer time intervals,
shutter was closed between acquisitions. X-ray damage was evaluated with
static  measurements to  guarantee its  absence from time-resolved collected
data.
Two-dimensional  images  were  circularly  integrated  to  obtain  one-
dimensional scattering profiles. After subtraction of the scattering profile of
the buffer  solution,  the radius  of  gyration,  Rg,  and  the  forward scattering
intensity,  I0,  were  calculated  using  the  Guinier  approximation,  where  the
scattering vector q=(4π/λ) sin θ (λ is the wavelength and 2θ is the scattering
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angle) and Iq is the scattering intensity at a given q value. The I0 and Rapp
values were calculated from the intercept and slope of the Guinier plot in the
q range satisfying q.Rg ≤ 1.3.
3.3 Lanthanide binding ferritin 
Protein design, expression and purification
A synthetic gene encoding for mouse H chain ferritin (MuHF) fused with a
lanthanide binding peptide (LBT) was designed, synthesized, and optimized
for  E.  coli codon  usage  by  Geneart  (Geneart  AG).  LBT  sequence
YIDTNNDGWIEGDELLA(Martin et al., 2007) was added to the C-terminal
of MuHF generating MuHF-LBT construct, that was subcloned into pET22-b
vector  (Novagene)  between  NdeI/XhoI  restriction  sites.  MuHF-LBT was
overexpressed  in  E.  coli  BL21 cells  upon induction  with  1  mM IPTG at
OD600nm = 0.6. Cells were harvested by centrifugation 16 hours post induction
at 37°C. Cells from 1 L culture were resuspended in 20 mM HEPES pH 7.5,
containing 300 mM NaCl,  1 mM TCEP, and a cOmpleteTM Mini Protease
Inhibitor Cocktail Tablet (Roche). Cells were disrupted by sonication and the
soluble  fraction  was  purified  by  heat  treatment  at  80°C  for  10  minutes.
Denatured E. coli proteins were removed by centrifugation at 15000 rpm at
4°C  for  1  hour.  The  soluble  protein  was  further  purified  by  ammonium
sulfate  precipitation.  The precipitated  fraction  at  70% ammonium sulfate,
was resuspended in 20 mM HEPES, 50 mM MgCl2,  pH 7.5 and dialyzed
versus the same buffer. As final purification step, the protein was loaded onto
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a  HiLoad 26/600 Superdex 200 pg column previously  equilibrated  in  the
same buffer using an ÄKTA-Prime system (GE Healthcare). Purified protein
was  concentrated  to  obtain  the  final  protein  preparation  of  1  mg/mL and
protein  concentration  was  calculated  by  measuring  the  UV  absorption
spectrum using an extinction coefficient of 32400 M-1 cm-1 . The expected
molecular  weight  of  22662  Da  was  confirmed  by  MALDI-TOF  Mass
Spectrometry.
Fluorescence spectroscopy
Fluorescence  spectra  and  titrations  were  performed  using  FluoroMax  4
(Horiba)  spectrofluorimeter  with  a  Haake  D8  refrigerated  bath  at  20  °C.
Emission spectra were recorded between 450 and 560 nm, in order to include
the  luminescent  maxima  of  Tb(III)  (490  and  545  nm).  The  excitation
wavelength was chosen at 295 nm to minimize the overlap of second order
diffraction (570 nm) with the Tb(III) emission at 545 nm. Emission spectra
were taken with excitation and emission band passes  of 4  and 8 nm and
corrected for the blank contribution and the instrument response at 295 nm in
a quartz cell of 1 cm pathlength. Emission spectra were normalized to 1 at
545 nm. Fluorescence measurements were performed using 1 μM apoMuHF-
LBT and apoMuHF as a control, in 100 mM MES buffer pH 6.4. A 50 mM
TbCl3 (Sigma-Aldrich) stock solution was also prepared in MES buffer at pH
6.4. Fluorescence spectra were recorded upon 30 min incubation with excess
of  TbCl3 in  buffer  solution  followed  by  a  washing  step  to  remove  the
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unbound metal. Titration data were obtained by addition of aliquots of TbCl3
in buffer solution under continuous stirring.
Cryo-Electron microscopy
Holey-gold grids from Quantifoil R1.2/1.3 (Quantifoil Micro Tools GmbH)
were prepared as described  (Russo & Passmore, 2014); their surfaces were
treated with plasma cleaning using a mixture of H2 and O2 and 3 μl of a
solution containing 1 μM MuHF-LBT Tb(III)  complex was applied to the
holey-gold grids.  After  30 seconds waiting time,  grids were blotted for 3
seconds at 100% humidity with filter paper and vitrified by rapidly plunging
into  liquid  ethane  at  −180  °C,  with  a  Vitrobot  Mark  IV  (FEI).  Data
acquisition  was  performed  using  a  FEI  Titan  Halo  (FEI,  Eindhoven)
operating at 300 kV, while the specimen was maintained cold using liquid
nitrogen. Datasets were collected with an automated data collection system
(Suloway  et  al.,  2005) on  a  K2  Summit  direct  detector  camera  (Gatan,
Pleasanton) operating in super-resolution mode, with a calibrated pixel size
of 1.15 Å on the object scale and a magnification of 59 000×. Images were
typically recorded with a defocus range between -0.7 and -3.0 μm and a dose
of electrons on the specimen plane between 10 and 20 electrons/Å2.  Data
analysis was carried out using RELION 2.0 (Scheres, 2012).CTF correction
was done using MotionCor2 (Zheng et al. 2016). Particles were picked and
extracted from the original micrographs with the reference based automated
particle picking procedure implemented in RELION and were 2D classified
using 100 classes. 2D good classes were selected and then subjected to 3D
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classification with 8 classes, using as reference model the MuHF structure
(PDB  code  3WNW).  Resulting  good  classes  were  refined  with  the  3D
autorefine procedure in RELION. The final 3D map resolution is calculated
with  the  FSC  =  0.143  criterion,  based  on  the  “gold-standard”  protocol
(Rosenthal & Henderson, 2003), using soft masks with a 4 pixel soft edge,
and has been corrected for the effects of the mask on the FSC curve using
high-resolution noise substitution  (Chen et  al.,  2013).  This final  map was
visualized using UCSF Chimera (Pettersen et al., 2004).
Crystallization and X-ray structure determination
Crystals of apoMuFH-LBT and MuHF-LBT-Tb(III) were obtained by mixing
in  a  2  μl  hanging  drop the  purified  protein  at  15  mg/ml  with  a  solution
containing 1.8/2.0 M ammonium sulphate and 0.1 M Tris pH 8.5, at 25° C
within  a  week.  Cryoprotection  of  crystals  was  attained  by  extensively
washing the crystals in sodium malonate followed by flash-freeze in liquid
nitrogen. Diffraction data were collected at  XRD1 beamline at  the Elettra
Synchrotron, Trieste, Italy. Data were processed with XDS  (Kabsch, 2010)
and scaled with Aimless (Winn et al., 2011) at a final resolution of 2.85 and
2.65 Å. The structures were solved by Molecular Replacement with Phaser
(Adams et al., 2010; McCoy et al., 2007) using the structure of MuHF (PDB
code 3WNW) as search model. Model building and refinement were done
using  Coot  (Emsley  &  Cowtan,  2004) and  Refmac5  (Murshudov  et  al.,
2011),  respectively.  The  final  model  was  analyzed  with  PROCHECK
(Laskowski et al., 1993) and Molprobity (Chen et al., 2010). Ramachandran
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plot showed more than 98 % residues were in preferred regions and no outlier
was observed in both structures. The validation of metal binding sites was
performed using CheckMyMetal web server  (Zheng et al., 2017). The final
atomic coordinates and structure factors were deposited with the PDB Data
Bank (www.rcsb.org) with accession code (5OBA and 5OBB, respectively).
Cell cultures and ferritins internalization
Human  prostate  cancer  cell  line  DU-145  (ATCC®  HTB81TM),  human
colorectal cancer cell line HCT-116 (ATCC® CCL-247TM), human breast
cancer  cell  line MDA-MB-231 (ATCC® HTB-26TM) and human ovarian
cancer cell line SKOV-3 (ATCC® HTB-77TM) were cultured in Dulbecco's
Modified  Eagle  Medium  (DMEM)  containing  10%  FBS,  100  μg/ml
streptomycin and 100 U/ml penicillin G in a humidified 37 °C incubator. The
internalization assay was performed as it follows: cells were detached using
trypsin, then washed twice with PBS and resuspended in non-supplemented
DMEM containing FITC - ferritin nanoparticles (MuHF-LBT or MuHF as a
control) at a final concentration of 0.5 mg/ml for 1 hour in a humidified 37°C
incubator.  After  incubation  cells  were  washed  three  times  with  PBS and
subjected to confocal microscopy and flow cytometry analysis.
Confocal microscopy
Following internalization step described above, cells were seeded into 8-well
NuncTM Lab-TekTM Chambered Coverglass with 200 μl DMEM, containing
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10% FBS, 100 μg/ml streptomycin and 100 U/ml penicillin G per well. Plates
with cells were then incubated on ice until visualization at the microscope.
Images were acquired using an inverted confocal microscope IX70 FV 500
(Olympus), with 488 nm laser, 20x objective lens and emission filter 505-560
nm.  Image  processing  was  performed  using  ImageJ  software  (National
Institutes of Health, www.imagej.nih.gov/ij/).
Flow cytometry analysis
Cells  were  incubated  with  FITC-ferritin  nanoparticles  as  described
previously  then  washed three  times  with  PBS,  and resuspended in  FACS
buffer (2% FBS, 1 mM EDTA). Internalization of ferritins before and after
treatments was measured at the BD FACS AriaTM III equipped with a 488
nm laser. Cells were first gated by forward and side scatter area (FSC-A and
SSC-A) plot and for singlets population (FSC-H and SSC-A), then detected
in  the  channel  for  FITC  expression  (530/30nm  filter)  and  side  scatter
parameter. The gate for the final detection was set according to the gate set
on the control  sample.  Data  were analyzed using BD FACS DIVATM and
FlowJo softwares.
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4 Results and discussion
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4.1 Archaeal ferritin’s permeation properties
Ferritins cages of archaeal origin have been proposed as privileged scaffolds
for  nanotechnological  applications  due  to  their  increased  thermo-stability,
and high yield expression in recombinant  E.coli expression systems and, in
the  case  of  Archaeoglobus  fulgidus ferritin  (AfFt),  for  its  uncommon
structure and association/dissociation properties, that result in the display of
four large triangular pores (45Å wide) in the protein shell. For all ferritins,
the pores and channels on the protein shell are responsible for the entry and
exit of cations during mineralization/demineralization. This characteristic has
been exploited in the development of ferritin based drug-carriers and pores
have  been  proposed  as  main  drug  loading  routes.  However  molecular
diffusion  in  and  out  of  the  ferritin  cavity  appears  to  be  a  complex
phenomenon only partially understood.
A set of mutated ferritins from A. fulgidus and P. furiosus were designed to
assess  the  accessibility  of  the  protein  cage’s  interior.  These  display
significantly different quaternary structures - whereas the PfFt 24-mer has the
canonical 432 point-group symmetry, the AfFt 24-mer displays a 23 point-
group symmetry typical of smaller 12-mer ferritin-like proteins. This unusual
assembly does not display the 4-fold channels and constrains the quaternary
structure  thus  leading to  the  appearance  of  four  large  triangular  openings
about 45 Å wide in the protein shell. In total, four mutants were designed to
bear cysteine residues in selected topological positions inside or outside the
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ferritin shell:  two PfFt  mutants,  one bearing cysteines  facing the cavity –
PfFt-G52C – and another with surface exposed cysteines – PfFt-P77C; two
AfFt  mutants,  both  bearing  cysteines  facing  the  cavity,  one  “open”,  i.e.,
displaying  the  four  large  pores  –  AfFt-M54C –  and  one  ‘closed’,  where
design mutations induce the canonical ferritin assembly – AfFt-M54C, AfFt-
M54C/K150A/R151A (Figure 4.1).
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Cage accessibility  was evaluated  by comparing  the  reactivity  of  the  thiol
reactive compound DTNB to strategically located thiol groups at the mutated
cysteines.
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Figure 4.1 –  Threedimensional structures of the ferritin mutants.  A monomer is
depicted as green ribbon and the cysteine residues are represented in CPK style for
clarity.  (A) Pf-FtP77C:  the external  cysteine  is  shown as  blue  spheres.  (B) Pf-
FtC52C: the internal cysteine is depicted in red. Models A and bB built on Pf-Ft
structure  (PDB code:  2JD6).  (C) Af-Ft54C:  the  internal  cysteine is  depicted in
purple. (D) Af-FtM54C/K150A/R151A: the internal cysteine in magenta. Mmodels
C  and  D  built  on  AfFt  structure,  (PDB code:  1SQ3).  Molecular  graphics  and
analyses were performed with the UCSF Chimera package. (Pettersen et al., 2004)
In order to assess the association state of the the engineered ferritins, DLS
and  SEC  studies  as  a  function  of  MgCl2  concentration  were  performed.
Although  PfFt  mutants  are  stable  24-mers  the  association  state  of  AfFt
mutants is  salt  dependent and MgCl2 was used as polymerizing salt.  At a
working concentration of 20 mM MgCl2, all mutants showed to be stable 24-
mers, with similar SEC elution profiles (Figure 4.2)
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Figure  4.2  – Size  exclusion  chromatography  profiles  of  ferritin  mutants.  The
characteristic SEC profiles obtained at 20mM HEPES pH. 7.4, 20mM MgCl2, for
mutants PfFt-P77C, PfFt-G52C, AfFt-M54C and AfFt-M54C/K150A/R151A (right
to left, top to bottom) are represented.
The kinetics  of  the  disulfide  exchange  reaction  of  DTNB with  cysteines
residues were carried using time-resolved UV spectroscopy, using stopped-
flow  technique.  Kinetic  traces  were  obtained  under  pseudo-first  order
conditions  and  followed  up  to  the  maximum  instrumentally  achievable
(1000s). As illustrated in Figure 4.3, the time scales of the four mutants differ
significantly:  the  PfFt-P77C mutant  bearing  the  surface  exposed  cysteine
displayed  the  fastest  reactivity,  followed  by  the  AfFt-M54C  the  “open”
mutant, then the “closed” AfFt-M54C/K150A/R151A and finally the PfFt-
G52C with  the  inner  cysteine.  Within  the  observed  time frame all  traces
could be fit to a simple relaxation process with apparent second order rate
constants as indicated in Table 4.1, with the notable exception of AfFt-M54C
that was fitted by A bi-exponential process in which the fastest second-order
rate constant was of the same order of magnitude as the PfFt-P77C mutant. 
Table 4.1 
Apparent second-order constants for ferritin mutants as determined by the DTNB
reaction
Protein Cysteine position Kobs (M-1s-1)
PfFt-P77C External 908 ±122
PfFt-G52C Internal 5 ±1
AfFt-M54C “open” Internal Fast: 198 ±65
Slow: 51 ±21
AfFt-M54C/K150A/R151A “closed” Internal 26 ±2
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To ensure and quantify the reaction completion, all mutants were submitted
to  LC-MS analysis  before  and  after  titration  with  DTNB.  In  all  samples
reaction was completed, with the exception of PfFt-G52C in with 18% of
cysteines remained unreacted. 
Overall these results show that the diffusion of molecules across the protein
shell  can  be  accurately  measured  and  that  bulky  molecules,  such  as  the
DTNB, can permeate the protein shell much better than expected. Even fully
assembled PfFt-G52C and closed AfFt-M54C/K150A/R151A mutant are able
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Figure 4.3 – Kinetics of DTNB binding to AfFt and PfFt mutants. Comparison of
the reaction time scales of all mutants; from left to right, Pf-FtP77C, Af-FtM54C,
Af-FtM54C/K150A/ R151A, and Pf-FtG52C. All mutants were 5 μM except Af-
FtM54C which was 4 μM, and DTNB was 0.7 mM.
to bind stoichiometrically the bulky, negatively charged DTNB. This indicate
that negatively charged of 8-10 Å length and 5-6 Å diameter are able to cross
the protein shell, in contrast with the previously described impermeability of
vertebrate  ferritins  to  negatively  charged  molecular  species.  The  charge
selectivity reported in HoSF and HuHF has attributed to the nature of the
threefold channels, endowed with hydrophilic, negatively charged residues
(Desideri et al., 1991). Moreover, kinetic studies of permeation using small
nitroxide  spin  probes  where  a  negatively  charged  nitroxide  probe  was
completely excluded from the cavity, and mutation of HuHF threefold lining
residues from negatively charged glutamate to histidines partially allowed the
entry of negatively charged species provide strong evidence of determining
role of the threefold channels ad charge-selective avenues for cavity entry
(Yang et al., 2000). In the case of PfFt, channels are similar to those of HuHF
in the outer side, that is rich in negative aminoacids (Glu109, Glu110 and
Glu111), whereas they differ in the central region due to the presence of polar
and  positively  charged  residues  (Tyr114  and  Arg117).  Lastly,  the  inner
opening  of  the  channel  displays  Ala118  and  Glu121  in  the  topological
position which is deemed essential for the transfer of Fe(II) to the ferroxidase
center in mammalian ferritins  (Behera & Theil, 2014). In the case of AfFt
mutants the cluster of negative charges characteristic of HuHF is not present.
The threefold channels are lined by a mix of hydrophobic and hydrophilic
aminoacids: only one glutamate (E131 is located at the entrance and the two
acidic residues D131 and E134 lining HuHF channels are replaced by neutral
and positively charged residues Y119 and N120). Presumably this might due
to the fact that is not necessary to drive Fe(II) atoms towards the ferroxidase
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site since they are readily available through the large pores present in the
protein  shell.  Hence,  the  threefold  channels  of  archaeal  ferritins  are  less
negatively charged than the mammalian ones, possibly allowing the entrance
of  negatively  charged  compounds.  Logically  in  the  AfFt-M54C  “open”
mutant, the large triangular pores are the most likely preferential paths for
bulky ligand entry, as denoted by the eight-fold faster DTNB reaction rate
when compared with AfFt-M54C/K150A/R151A.
Thus,  on  the  basis  of  the  observed  DTNB  binding  rates  and  available
crystallographic structures it  is  possible to  conclude that  archaeal ferritins
from P. furiosus and  A. fulgidus are able to incorporate negatively charged,
modestly sized diffusants, even in their fully “closed” forms, likely through
the threefold channels whose nature appears less restrictive with respect to
that of vertebrate proteins. 
 It must also be pointed out that the dimensions of DTNB slightly exceed the
diameter of the threefold channel inferred from crystal structure coordinates.
A mechanism considering rotameric adjustment of involved aminoacid side
chains is thus necessary in order to allow for the entry/exit of small organic
molecules.  Recent  demonstration  of  multiple  conformers  in  aminoacids
lining  the  inner  entrance  to  the  ferritin  cavity  may explain  the  necessary
plasticity of the threefold channels in ferritins (Behera & Theil, 2014).
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4.2 Humanization of an archaeal ferritin
Human  ferritin  has  been  extensively  investigated  as  a  protein  carrier  for
biotechnological applications and represents a promising alternative to viral
carriers  for  targeted  delivery  of  anticancer  drugs  and  imaging  agents.
Moreover, ferritins are naturally targeted toward ubiquitously expressed TfR1
transferrin  receptors.  Such  properties  have  been  widely  exploited  for  the
efficient  delivery  of  anti-tumor  drugs  to  iron-avid,  fast  replicating,  tumor
cells  overexpressing  TfR1.  However,  the  most  relevant  limitation  to  their
application  is  the  need  for  acidic  experimental  conditions  to  induce  its
disassembly,  a  fundamental  step  in  order  to  achieve  encapsulation  of  the
cargo within the internal cavity. These extreme experimental conditions could
affect both drug stability and compromise complete reassembly of the ferritin
cage when pH is restored to neutrality, resulting in poor cargo load efficiency.
To  overcome  this  issue,  the  unique  scaffold  of  A.  fulgidus ferritin  was
genetically engineered to mimic the peptidic sequence of the surface exposed
BC loop of the analogous human H-chain ferritin. This new chimeric protein
–  HumAfFt  –  was  shown  to  maintain  the  unique,  salt-dependent
association/dissociation properties of AfFt while exhibiting the typical HuHF
recognition by TfR1.
4.2.1 “Humanized”A. fulgidus ferritin design
HuHF and AfFt display 31% sequence identity. The structural alignment of
HuHF and AfFt monomers (PDB code 3AJO and 1S3Q, respectively) reveals
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a shorter N-terminus and shorter loops between three of the four helices, with
the exception of the long loop connecting B and C helices (Figure 4.3).
The  BC  loops  of  two  adjacent  subunits  run  in  an  antiparallel  fashion
establishing mutual interactions. Thus, BC loops of adjacent subunits display
the same overall geometry in both HuHF and AfFt, though each couple of
loops adopts a different symmetry along the spherical surface of the protein
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Figure  4.3  – Sequence  alignment  of  AfFt,  HumAfFt  and  HuHF.  Elements  of
secondary structure for the AfFt are shown on the top. White characters in a red
background indicate strict conservation while residues with poor conservation are
drawn in black on a white background. Alignments were made using CLUSTAL
Omega, and the figure was generated using ENDSCRIPT.(Robert & Gouet, 2014)
cage, given the different dimer-dimer positioning within each complete 24-
mer structure (Figure 4.4).
In  order  to  preserve  the  unique  assembly  properties  of  AfFt,  while
implementing a potential cellular uptake, the the key residues involved in the
stabilization  of  the  symmetric  protein  architecture  were  determined  using
Pisa software (Krissinel & Henrick, 2007) and analyzing the crystal structure
as  a  guide.  Hydrophobic  interactions  are  very  largely  spread  and  deeply
contribute for the stabilization of 24-meric state. Analysis of the interactions
stabilizing dimers in the 24-meric state identified two H bonds,  involving
residues Lys150 and Lys151, as critical for the stabilization of the “open”
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Figure 4.4 – Three dimensional structures determined by X-ray crystallography. A
cartoon representation of  (A)  HumAfFt  (B) HuHF (PDB code 3AJO). Models are
colored blue and green, respectively and external loop connecting the helices B and
C of each monomer is shown in red. Images were made using the UCSF Chimera
software (Pettersen et al., 2004).
pore conformation. In fact, Sana et al, obtained a “close” conformation by
mutating these two residues  (Sana et  al.,  2013).  A summary of  hydrogen
bonds and salt bridges formed between chain A and B and the other subunits
of the 24-mer are listed in Table 4.2.
Table 4.2 
Interactions of chains A and B with the remaining chains of the 24-mer AfFT (PDB:1S3Q)
Position 1 Position 2 Distance (Å) Type
Chain A
Ile146 (O) F: Lys150 (NZ) 2.9 H bond
Asp149 (OD1) F: Lys151 (N) 3.8 H bond
Glu108 (OE1) E: Lys114 2.7 Salt bridge
Glu108 (OE2) E: Lys114 3.8 Salt bridge
Lys114 D: Glu108 (OE1) 3.3 Salt bridge
Lys114 D: Glu108 (OE2) 3.9 Salt bridge
Lys150 (NZ) H: Mse111(O) 2.8 H bond
Chain B
Arg151 (N) D: Asp149 3.7 H bond
Mse111 (O) G: Lys150 3.2 H bond
Tyr119 L: Arg151 2.7 Salt bridge
After these considerations, the external BC loop was determined as the most
favorable location for redesigning the AfFt scaffold with the corresponding
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residues in HuHF, taking in account the sequence alignment shown in figure
4.3. The external loop spans from residue 66 to 83 (AfFt numbering) and has
a highly conservative region between archaea and human ferritin (RGGR) at
the beginning, and a conservative tryptophan at the end of the loop. A total of
nine aminoacids differ between HuHF and AfFt in the nineteen residue long
loop,  and  these  were  mutated  in  order  to  match  HuHF’s  sequence.  In
addition,  a  cysteine  residue  in  position  54  (AfFt  numbering)  has  been
introduced  by  point  mutation  in  order  to  provide  a  conjugation  site  for
potential thiol reactive derivatives moieties into the cavity.
4.2.2 Structural characterization
The HumAfFt crystallized in a different condition with respect to wild type
AfFt. Crystals were exposed to x-rays from a synchrotron in order to confirm
the  tetrahedral  symmetry  reported  for  archaeal  ferritins.  The  protein  was
crystallized in the presence of Mg2+ in order to maintain the 24-mer assembly.
The structure of HumAfFt has been determined by X-ray crystallography at a
2.87 Å resolution. It crystallized in the C2221  space group, as observed also
for  wild type  AfFt.  The asymmetric  unit  (ASU) contains  twelve identical
subunits with a solvent content of 64.3 %. Data collection and refinement
statistics are reported in Table 4.3. 
The overall folding corresponded to the wild type AfFt structure (pdb code:
1S3Q) with a root mean square deviation (rmsd) value of 0.4 Å and displayed
four  wide  triangular  pores  on  the  surface  (Fig  4.4.A).  B-factors  analysis
shows  a  mean  B  factor  of  66  Å2 with  the  exception  of  the  loop  region
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between the D and E helices, which displays higher B-factors and a poor
electron density on the side chains from 146 to 151 residues. Conversely, the
BC loop is well organized and the analysis of the difference electron density
(Fo-Fc) map clearly showed the presence of the mutated residues in the loop
between helices B and C as well as the M54C mutation, pointing towards the
inner cavity.
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Table 4.3 
Data collection and refinement statistics for the crystal structure of HumAfFt.
*Numbers in parentheses refer to data in the highest resolution shell.
*Rfree was computed omitting 5% of the reflections as a test set.
Data collection
Space Group C2221
Cell Dimensions
a, b, c (Å)
185.80 190.65 176.54
Resolutions (Å) 48.86 - 2.94 (3.00 - 2.94)
Rmerge 0.134 (0.751)
Unique reflections 59926 (4378)
I/σI 7.8 (1.8)
Completeness (%) 95.8 (95.6)
Redundancy 4.2 (4.3)
Refinement
Resolution (Å) 49.69 - 2.94 (3.00 - 2.94)
No. reflections 56823 (346)
Rfactor 0.27 (0.61)
Rfree 0.30 (0.59)
Ions (Mg2+) 2
Water molecules 13
r.m.s. deviations
Bond lengths (Å) 0.007
Bond angles (o) 0.99
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Two magnesium ions have been positioned and successfully refined in the
ASU, located in the ferroxidase site of two different subunits. In both, one
magnesium ion is coordinated with both OE1 and OE2 of Glu19, (at 2.5 Å
and 2.8 Å distance, respectively), with Glu52 (OE1) at 2.5 Å, with Gln129
(OE1) at 2.6 Å and with a water molecule at 2.6 Å distance. In the other
chains,  a  water  molecule  has  been  modeled  in  the  Fo-Fc  map  and
successfully refined in the same position (Figure 4.5).
The  loop  region,  including  the  conserved  terminal  turns,  spans  from
aminoacid  68  to  aminoacid  86.  The  structural  superposition  between
HumAfFt and the HuHF, as well as between HumAfFt and AfFt, are shown
74 
Figure 4.5 –  Magnesium ions at modeled at HumAfFt ferroxidase center.  (A) Mg
sphere of coordination at chain I with aminoacids E19, E52, E96, E132, Q129 and a
water molecule.  (B) Mg sphere of coordination at chain F with E19, E52, Q129,
H55  and  a  water  molecule.  Images  were  made  using  UCSF Chimera  software.
(Pettersen et al., 2004)
in Fig. 4.6. At the dimeric interface between the two antiparallel BC loops,
the  main  interactions  are  a  hydrogen  bond  between  Arg69(NH2)  and
Ser80(O)  at  2.8  Å  distance  and  two  salt  bridges,  namely  Lys71(NZ)  -
Glu77(OE1)  at  3.0  Å  distance  and  Glu81(OE2)  -  Arg69(NH1)  at  2.7  Å
distance. A weak salt bridge is established by Glu81(OE2) and Arg69(NH2),
at a distance of 3.0 Å. The salt bridge between Lys71 and Glu77 observed in
HuHF  is  absent  in  HumAfFt  since  these  positions  were  mutated  into  a
phenylalanine (Phe71) and a lysine (Lys77). Other interactions are conserved
between HuHF and HumAfFt and displayed the same distances.
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Furthermore,  HumAfFt  structure  in  solution  was  probed  by Cryo-EM,  in
order to asses the three-dimensional assembly in a near native environment.
Single  ferritin  particles  were  visualized  at  a  nominal  resolution  of  33  Å
demonstrating that their shape and dimensions correspond to those of AfFt.
Moreover, the triangular pores on the protein surface were observable in bi-
dimensional views and clearly visible in three-dimensional reconstructions
(Figure 4.7)
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Figure  4.6  –  Structural  superposition  of  the  region  from  R69  to  S84  (AfFt
numbering). (A) HumAfFt  vs.  HuHF  (B) HumAfFt  vs.  wt  AfFt.  Residues  are
depicted as stick,  with N atoms shown in blue,  O atoms in red and S atoms in
yellow. Images were made using UCSF Chimera software.(Pettersen et al., 2004)
4.2.3 Cellular uptake of Humanized ferritin
After demonstranting that HumAfFt maintains its structure with large open
pores  we  aimed  to  verify  that  the  chimeric  version  was  susceptible  to
internalization by eukaryotic cancer cells such as HeLa cells. It is known that
HuHF is recognized and internalized by the TfR1, which is overexpressed in
many types of tumor cells but not in normal cells and healthy tissues. To
validate the effect of introduced mutations on the external loop in influencing
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Figure 4.7 – Cryo-EM characterization of HumAfFt. (A) Sample micrograph of the
HumAfFt. Scale bar: 100 nm.  (B) Five representative 2D class averages obtained
with RELION.  (C) 3D reconstruction of HumAfFt obtained with RELION. Map
final resolution: 33.1 Å. Scale bars: 10 nm. Left: side view. Right: top view.  (D)
AfFt crystal structure (PDB code 1S3Q) filtered to 30 Å, shown for comparison.
Scale bars: 10 nm. Left: side view. Right: top view.
the uptake efficiency by HeLa cells, time course experiments on cells treated
with the same amount (30 µg ml−1) of AfFt, HumAfFt and transferrin labeled
with FITC fluorescent  moiety  have been performed and analysis  by flow
cytometry  carried.  As  a  baseline  for  FITC fluorescence,  control  cells  not
incubated with FITC-ferritins  were used.  Moreover,  to exclude any signal
generated  from  outside  particles  sticking  on  the  cell  membrane  due  to
unspecific binding or remains from the washing steps, trypan blue quenching
was  performed  before  using  FACS.  In  figure  4.8,  the  FACS  analysis  is
summarized,  shown  as  the  percentage  of  cells  internalizing  the  ferritin
nanoparticles  at  different  times.  These  data  highlighted  that  HumAfFt
nanoparticles are efficiently taken up by HeLa cells already after one hour
incubation with a much higher percentage compared to AfFt (81% and 5%
respectively). After a longer incubation time (20 hours), the FITC-positive
cells  for the humanized samples increased to more than 90% whereas for
native AfFt they were still less than 20%. The latter increment is possibly due
to the unspecific uptake by pinocytosis.
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Moreover, RNAi experiment against the transferrin receptor were performed
and analyzed the cellular uptake by FACS, obtaining around 50% HumAfFt
uptake  reduction  after  48  hours  of  siRNA transfection,  confirming  the
involvement of TfR1 in the internalization process (Figure 4.9)
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Figure  4.8  –  Internalization  of  ferritins  by  Hela  cells,  measured  using  Flow
Cytometry.  HumAfFt  is  internalized  with  higher  efficiency than  the  wild  type.
Cells have been treated with 30 µg ml−1 of AfFt-FITC, HumAfFt-FITC and Tf-
FITC. The percentage of cells internalizing the nanoparticles at the time indicated
is shown. For each sample 30 000 events gated on live cells have been acquired.
In  order  to  visualize  uptaken  HumAfFt–FITC  nanocages,  internalization
assay  directly  on  an  ibidi  8-well  µ-slide  was  executed,  where  cells  were
incubated for  20 hours before confocal  microscopy.  The properties of the
HeLa TagRFP cell lines available in the lab were exploited for obtainment of
a reference fluorescence signal confirming that imaging was occurring inside
the cell. This cell line contains a TagRFP-FUS protein under the control of a
doxycycline-inducible promoter that allows for a controlled expression of the
protein and hence permits visualization of the nucleus in the red channel. The
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Figure 4.9 –  HeLa cells  transfected with control  (scrambled) and specific anti-
TfR1 siRNA were incubated with Hum AfFt-FITC for 24 and 48 hour,. After 3
hours cells  were collected, washed and analyzed at the cytometer for the FITC
fluorescent intensity. Compared to the FITC intensity in control cells (scrambled)
an uptake reduction of almost 50% after 48 hours of RNAi was obtained.
cells  were  not  selected  to  eliminate  the  untransfected  cells,  allowing  to
visualize  different  levels  of  expression  and  unstained  nuclei.  Just  before
imaging, the cells were washed to eliminate the unbound FITC-nanoparticles
and  then  acquired  by  confocal  laser-scanning  microscopy.  Confocal
representative images of the entire field of view of live HeLa TagRFP cells
alone (control) or incubated with HumAfFt-FITC or Tf-FITC are shown in
figure 4.10 A. A detailed view of the boxed region in panel A is shown in
figure 4.10 B. Images confirmed the high extent of HumAfFt internalization
and highlighted a cellular distribution in the cytoplasm and in the perinuclear
space comparable to that observed for transferrin, thus suggesting a typical
clathrin-coated endocytosis pathway, mediated by TfR1.
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Figure 4.10 –  Ferritin internalization observed at the confocal microscope. Cells
were  plated  on  an  8-well  µ-slide  (ibidi),  induced  with  doxycycline  to  express
TagRFP and then incubated with 30 µg ml−1 of HumAfFt-FITC or Tf-FITC for 20 h.
After washing, cells were live-imaged using a con- focal microscope. (A) Confocal
images of live HeLa TagRFP cells are shown as single, merged channels and overlay
images with the phase contrast. Scale bars: 40 µm. (B) Images are a magnified view
of the region highlighted by the white inset in panel A; merged channels and the
overlay with the phase contrast images are shown. Scale bars: 10 µm.
4.2.4 Humanized ferritin self-assembly
HumAfFt was designed to retain most structural features of its scaffold, such
as the tetrahedral 32 symmetry that results in the appearance of four large
triangular apertures in the protein shell, as well as the larger cavity volume of
~325 Å with respect to ~261 Å for canonical ferritins. But more importantly
it was designed to maintain the unique self-assembly/disassembly properties
observed in AfFt. This protein it is stable as a dimer in neutral  low ionic
strength  conditions  and  self-assembles  at  high  ionic  strength  or  in  the
presence  of  divalent  cations  (Sana  et  al.,  2015).  However,  key
thermodynamics and kinetics properties related to the assembly of HumAfFt
are only partially understood.
In order to confirm the salt induced self-assembly, DLS measurements were
carried in the absence and presence of 30 mM MgCl2, for HumAfFt and AfFt,
and  the  population  distribution  by  diameter  obtained.  The  hydrodynamic
diameter  (dh)  corresponds  to  the  size  of  a  hypothetical  hard  sphere  that
diffuses at equal speed as the particle under examination. Both proteins show
similar population size-distribution before and after addition of MgCl2 with a
clear  transition  from  small-size  population  of  particles  to  another  with
significantly bigger particles. The calculated dh of HumAfFt increases from
5.8 to 14.8 nm, in a similar fashion to AfFt whose dh goes from 5.6 to 12.9
nm. These results are compatible with the transition from an unassembled
state, most likely a dimer, to a fully assembled 24-meric ferritin. Additionally,
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the absence of other major peaks, indicates that intermediates species formed
during assembly are likely to be highly unstable.
The the thermodynamics of the effect of MgCl2 on HumAfFt’s assembly was
investigated  by  means  of  ITC.  To  a  solution  of  protein,  increasing
concentrations of MgCl2 were added and the heat transfer measured upon
each injection. A representative titration profile is reported in figure 4.12, in
which  data  was  tentatively  fitted  with  a  ‘one-site  binding  model’  for
calculation of thermodynamic signature of the phenomenon (Table 4.4). This
model assumes a unique binding site per monomer, an assumption neither
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Figure  4.11  – Evaluation  of  population  size-distribution  by  DLS.  Diagram  of
intensities per size, comparing the HumAfFt and AfFt, before and after addition of
30mM MgCl2. Protein concentration was kept fixed at 2mg/mL.
proved or disproved with the current experiment, however the model find its
utility in estimating thermodynamic parameters. Furthermore, a ratio of eight
magnesium ions per each monomer was calculated as the needed amount to
initiate the observed transition. The thermodynamic profile shows a positive
and small ΔH contribution, mostly unfavorable, with a positive and favorable
TΔS, of higher magnitude.  This strongly suggests that hydrophobic forces
dominate the assembly reaction.  The huge entropic favorable contribution
may report to the disruption of an organized hydration shell around the apolar
patches on the solvent exposed surface with the subsequent release of water
molecules.  This  has  been  been  reported  for  other  events  involving  the
formation  of  supramolecular  structures,  like  the  case  of  self-assembling
peptides and viral capsids (Hagan, 2014; Kabiri & Unsworth, 2014). 
Table 4.4 
Thermodynamic  parameters  calculated  with  a  one-site  binding  model  for  curve  fitting.
*Values reported are the mean of three independent experiments.
 ΔH 
(cal/mol)
 ΔS (cal/mol/
deg)
 ΔG (cal/mol) Kapp 
(mM)
n
323.3±46.2 20.3±1.2 -5739.1±405.9 0.09±0.02 7.8±0.8
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In  order  to  obtain  more  detailed  structural  information  on  the  assembly
between  dimer  and  24-mer  in  HumAfFt,  the  SAXS  profiles  obtained  at
increasing MgCl2 concentrations were obtained and displayed in figure 4.14.
SAXS is able to provide structural information of native proteins in solution
and the structural changes in response to varying conditions. It can probe the
macromolecular  size,  shape  and  oligomeric  state  of  a  complex  without
recurring to labeling (Koch et al., 2016; Svergun & Koch, 2003).
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Figure 4.13 – Microcalorimetric titrations of HumAfFt with MgCl2: (A) Raw ITC
data of titration of 15 μM protein monomer solution with 4 mM MgCl 2 (upper
panel) and, in the lower panel, integrated peak areas (black squares) fitted with the
one-binding-site model.  (B) Thermodynamic signature of the titration reported in
(A) whose thermodynamic parameters are listed in Table 4.4.
The shapes of the obtained SAXS curves reveal a significant shape change
corresponding to a structural transition from a dimer, to a spheric like final
state,  compatible  with  a  24-mer,  in  concordance  with  the  theoretical
scattering curves calculated using CRYSOL (Figure 4.14)  (Svergun et  al.,
1995) 
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Figure 4.14 – HumAfFt SAXS profiles. (A) Changes in SAXS curves of HumAfFt
at increasing MgCl2 concentrations. Curves were obtained at 2.5mg/mL protein, and
MgCl2 concentrations  are  reported in  the  legend.  (B) Comparison of  theoretical
scattering curves with the corresponding first and last experimental curves (0 and
30mM  MgCl2,  respectively).  Theoretical  scattering  curves  were  obtained  with
CRYSOL (Svergun et al., 1995) 
From these experimental scattering profiles, the radius of gyration (Rg) and
the  forward  scattering  intensity  I0 were  estimated  with  the  Guinier
approximation and plotted in Figure 4.15 . In a monodisperse solution, Rg is a
parameter  that  reflects  the  size  of  that  particle  population,  however  in  a
complex system where polydispersity  is  inherent,  the Rg is  not  simply an
arithmetic  average  of  the  Rg of  all  present  population  but  rather  biased
towards  to  the  values  of  larger  scattering  particles.  Conversely,  I0 is
proportional  to  the  mass  concentration,  the  molecular  weight,  the  beam
intensity, and the square of the difference between the particle and the solvent
(Putnam et al., 2007). In this system, both I0 and Rg increased in function of
MgCl2 concentration with slightly different profiles.
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The SAXS data, in accordance with the DLS data, indicate that dimer and 24-
mer  are  the  dominant  species  at  equilibrium  and  that  the  population  of
intermediates is negligible. Analysis of each single SAXS curve can in fact
fully accounted for by the sum of the scattering profiles corresponding to the
calculated scattering curved for the dimeric and 24-meric structures.
The sharp sigmoidal shapes of the curves hints to the high cooperativeness of
the assembly process.  Cooperativity can be the result  of the formation of
mutually  supporting  interactions,  or  a  much  more  subtle  consequence  of
conformational changes that occur upon binding. In the case of HumAfFt, the
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Figure  4.15  –  HumAfFT MgCl2 dependent  assembly.  Protein  at  2.5mg/mL was
titrated with increasing MgCl2 concentrations and the SAXS profiles collected, at
equilibrium. Rg and I0 were determined using the Guinier approximation. Rg values
plotted in blue and I0 in red.
cooperativeness  observed is  likely to  be due to  the the formation of new
interfaces  with  every  binding  event  between  subunits.  Nevertheless,  the
triggering effect of MgCl2 on inducing small structural transient states more
prone to  bind and undergo full  assembly,  is  an hypothesis  that  cannot  be
excluded here.
To  investigate  the  MgCl2 dependent  kinetics  of  the  HumAfFt  assembly
SAXS curves were collected at different time-delays upon reaction triggering
(Figure 4.16). At each time-delay, the resulting scattering curve is a product
of  all  present  intermediates  SAXS  curves  weighted  by  their  molar
concentrations. Although in theory, deconvolution of the SAXS curves could
provide  structural  information  on  the  intermediates  and  their  respective
concentrations,  in  reality  the  lack  of  information  on  possible/expected
intermediates combined with the lack of adequate structural models for those
intermediates  makes  this  task  virtually  impossible.  Nevertheless,  by
following  the  Rg in  function  of  time,  useful  information  on  the  system
kinetics can be extracted that can provide clues into the complexity of the
assembly mechanism. In figure 4.16, evolution of the Rg in function of time,
for three selected MgCl2 concentrations, reveals a sigmoidal profile typical of
multistep reactions (Endres & Zlotnick, 2002). Moreover, the overall reaction
rate is shows dependency on MgCl2 concentration, as the kinetic traces are
shifted to the left with increasing MgCl2 concentrations. In fact, it a bigger
portion  of  the  initial  part  of  kinetic  trace  is  lost  with  increasing  MgCl2.
Despite  the  lack  of  information  at  shorter  time-delays,  these  profiles  are
compatible with a nucleation-growth mechanism, similarly to what has been
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proposed by Zlotnick et al. for the assembly of HBV capsids (Zlotnick et al.,
1999). In this model, the assembly is described as a cascade of low-order
reactions  and  the  kinetics  predicted  to  be  sigmoidal  where  intermediates
hardly accumulate during the greater part of the reaction. The rate limiting
step is the formation of a discrete oligomer more prone to assemble – the
‘nucleus’ - whose size can be inferred from the concentration dependency of
the initial assembly rates (Zlotnick et al., 1999; Zlotnick et al., 2000). Based
on  these  Hagan  et  al.,  determined  that  the critical  nucleus  size  can  be
determined from the concentration dependence of the assembly half-life and
that  the  elongation  time  can  be  revealed  by  the  length  of  the  lag  phase
(Hagan & Elrad, 2010). 
Figure  4.16  –Time-dependent  changes  during  the  HumAfFt  assembly.  Rg time-
dependent  increase  upon  rapid  mixing  of  3  mM,  6  mM  and  30  mM  MgCl2.
Experiements were carried at 2.5 mg/mL in 20 mM HEPES pH 7.4.
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Fundamentally,  most  quaternary interactions  are  shared between AfFt  and
canonical  ferritins  up  to  the  hexameric  assembly  i.e.,  one-quarter  of  the
tetraeicosameric  shell.  As  a  consequence,  the  3-fold  symmetric  channel
formed at the center of each hexamer is conserved among all ferritins. The
key  difference  thus  resides  on  how the  hexamers  are  joined  to  form the
tetraeicosamer.  In  canonical  ferritins,  the  hexamers  are  joined  by  4-fold
symmetry  elements  whereas  in  AfFt,  the  hexamers  are  faced  in  a  2-fold
symmetry.  Thus,  specific  amino  acid  residues  at  the  hexamer–hexamer
assembly are the most likely locations that govern whether the symmetry is
tetrahedral  or  octahedral.  In  AfFt,  the  side  chains  of  Lys150 and Arg153
appear to function as molecular doorstops,  impairing the formation of the
canonical  octahedral  symmetry.  In  contrast,  a  set  of  AfFt  exclusive  H-
bonding and hydrophobic interactions contributes to the stabilization of the
unique  hexamer–hexamer  interface  thus  giving  rise  to  the  unusual
tetraeicosameric  structure  (Johnson  et  al.,  2005;  Sana  et  al.,  2015).
Nevertheless, the available structural information on the HumAfFt smaller
assembly units, the dimer and hexamer, is strongly biased towards the rigid
conformation of the 24-mer, as increased flexibility leads to instability and
usually  results  in  difficulty  in  crystallization  and  low  resolution  crystal
diffraction (Yu et al., 2000)
For  the  assembly  to  occur  spontaneously,  the  final  formed  cage  must  be
lower in free energy than the initial state with free subunits. The assembly is
expected to reduced translational  and rotational  entropy and thus must be
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driven by formation of favorable subunits and the components that overcome
this penalty. Thus, as with most protein-protein interactions, ferritin assembly
is likely driven by a complex combination of hydrophobic, electrostatic, van
der Waals and hydrogen bonding interactions (Hagan, 2014)
In many ways, the HumAfFt assembly resembles that of a viral capsid. The
thermodynamic signature obtained with ITC showed that assembly is largely
driven by hydrophobic forces. Similarly, Ceres and Zlotnick verified that the
thermodynamic stability of HBV viral capsids increases, on one hand, with
temperature,  suggesting  that  hydrophobic  interactions  are  the  dominating
driving forces; and on the other hand, with ionic strength implying that salts
play a role in screening the repulsing electrostatic interaction opposing to
subunit  association  (Ceres  &  Zlotnick,  2002).  Models  based  on  these
assumptions  have  successfully  been  able  to  reproduce  the  dependence  of
protein-protein interactions on ionic strength (Kegel & van der Schoot, 2006;
Šiber et al., 2012) and it has been proposed that higher salt concentrations
could  enhance  assembly  by  favoring  conformations  active  for  assembly
(Ceres  &  Zlotnick,  2002;  Hagan,  2014).  Assembly  kinetics  too  show
resemblance to those described for viral capsid assembly (Chen, et al., 2008;
Endres & Zlotnick, 2002; Johnson et al., 2005; Zlotnick et al., 2000). Viral
capsid  and  ferritin  assembly  share  a  set  of  common  features  such  as
sigmoidal kinetics of capsid growth starting with a lag-phase followed by a
rapid increase that then reaches a plateau, intermediates are not accumulated
during assembly. 
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The present data offer a clear frame for the understanding of the key features
of HumAfFt MgCl2 dependent assembly, that pave the way to proposing a
relevant mechanism of assembly for this unusual ferritin.
4.3 Lanthanide binding ferritin 
Among all the ferritin-based systems for bioimaging that have been created
only a few find application in fluorescence based techniques. To meet these
needs, a novel construct has been engineered in which a lanthanide binding
tag (LBT) was genetically fused to the C-terminal end of mouse H-ferritin
(MuHF). Fluorescent probes based on trivalent lanthanide ions are becoming
widespread  due  to  their  photo-physical  properties.  One  of  their  main
advantages is their long lifetime of the excited state, that allows the specific
signal  from  the  lanthanide  to  be  temporally  separated  from  background
signal. Lanthanide fluorescence life-times are in the milisecond time-range,
while fluorescence arising from other sources such as reagents, plastics, cell
environment are in the pico to microsecond time-range. This allows for the
use of a technique often referred as time-resolved fluorescence, where the
lanthanide  fluorescence  emission  signal  is  acquired  after  the  background
signal has completely decayed. Other advantages of lanthanide include: their
large Stokes’s shift,  i.e., excitation of lanthanides occurs in the UV region
while emission happens at  longer wavelengths,  normally greater  then 200
nm; and their narrow emission peak, that simplify the simultaneous use of
multiple labels as emission peaks are less likely to overlap (Handl & Gillies,
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2005). Despite this, lanthanides have inherent low extinction coefficients, and
fluorescence emission is quenched in non-radiative processes (Bünzli, 2015).
These issues have been addressed by the use of small  organic fluorophores,
in  Forster  resonance  energy  transfer  (FRET)  -  like  systems,  where  the  a
sensitizer fluorphores absorbs light in the UV region and transfer it to the
lanthanide ion emitting in the visible region, in a phenomenon often referred
as “antenna effect” (Selvin, 2002). Among lanthanides, Tb(III) is one of the
most interesting due to their more intense microsecond fluorescence in the
visible  region  (Bünzli  &  Piguet,  2005).  A  straightforward,  potentially
generalizable approach has been designed for the incorporation of lanthanide
ions into biomolecules consisting of genetically engineering proteins to co-
express a short peptidic sequence able to bind lanthanides – a lanthanide-tag.
These  have  been developed on the  basis  of  known properties  of  calcium
binding loops and resulted in the development of short sequences with 20 or
less amino acids with low-nanomolar affinities to target ions and selectivity
towards  lanthanides  over  other  metals  (Franz  et  al.,  2003;  Martin  et  al.,
2007).
Native apoferritins have been report  to  naturally  bind Tb(III)  within their
ferroxidase  center  at  the  three  fold  channel  and  at  a  third  unidentified
location  likely  corresponding  to  the  nucleation  site  (Bou-abdallah  et  al.,
2003). However, the distance between Terbium ions and aromatic moieties in
ferritins  made  the  FRET  efficiency  poor  and  suboptimal  for
fluorescence/luminescence based measurements. To improve both lanthanide
binding  to  ferritins  and  their  fluorescence  properties,  a  short  amino  acid
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sequence, initially designed by Martin et al.  (Martin et al., 2007), has been
engineered at the C-terminal end of MuHF, pointing to the cavity interior,
with  a  tryptophan  strategically  located  for  FRET purposes  and  resulting
chimeric  protein  called  MuHF-LBT  (Figure  4.17).  The  successful
introduction  was  cofirmed  by  MALDI-TOF  Mass  spectrometry  with  an
expected molecular weight of 22662 Da.
4.3.1 Binding of Terbium to MuHF-LBT
In order to assess the binding of terbium to MuHF-LBT, the fluorescence
emission  spectra  was  recorded  and  compared  to  wild  type  MuHF,  upon
excitation at 295 nm (Figure 4.18). The intensity of the fluorescence at 544
nm was  at  least  two  orders  of  magnitude  higher  with  respect  to  MuHF,
showing that the introduction of the LBT was successful in improving Tb(III)
fluorescence properties. The characteristic band at 544 nm in the MuHF-LBT
loaded with Tb(III) was visible down to 4 pM of protein concentration and
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Figure 4.17 – Representation of Lanthanide binding site adapted from Martin et al
(Martin et al., 2007)
neither  dialysis  nor  size-exclusion  chromatography  were  able  to  remove
bound Tb(III), revealing high affinity binding.
Furthermore, titration of MuHF with increasing Tb(III) concentrations were
performed,  where  a  1.7  equivalent  amount  of  Tb(III)  per  monomer  was
calculated  as  endpoint.  Carrying  the  same  titration  using  wt  MuHF
demonstrated a negligible contribution to fluorescence of Tb(III) located at
the ferroxidase center and three-fold channels. These results point out that the
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Figure 4.18 – Fluorescence spectra of MuHF-LBT Tb(III) complex (pink line) and
MuHF  Tb(III)  complex  (blue  line)  at  the  same  protein  concentration  (1  μM).
Spectra were recorded after 1 h incubation time with TbCl3  in 0.1 M MES buffer
pH 6.4.
introduced  LBT  is  able  to  bind  Tb(III)  and  efficiently  increase  the
fluorescence of terbium, using the tryptophan as a FRET donor to terbium,
resulting in two narrow emission bands at  490 and 544nm. Knowing that
Tb(III) is able to bind at the ferroxidase center in average one Tb(III) per
monomer, and that the full 24-mer is able to bind Tb(III) at the three-fold
channels, and assuming one Tb(III) per LBT, one would expect maximum
reached fluorescence to be maximal around 2.3 equivalent amount. However
the lower 1.7 indicates that despite the high affinity binding, the LBT are
likely not fully occupied.  This suggests that the ferritin cage environment
affect the structure of the introduced LBT.
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Figure 4.19 – Fluorescence titration of MuHF-LBT with Tb(III). (A) Fluorescence
titration  of  MuHFt-LBT (1  μM)  with  incremental  concentration  of  Tb(III)  (0–4
equivalents) in 0.1 M MES buffer pH 6.4. Emission spectra were recorded in 1 cm
pathlength cuvette upon excitation at 295 nm. (B) Fluorescence intensity of MuHFt-
LBT Tb(III)  complex as a function of the Tb(III)/MuHFt-LBT ratio. Fluorescent
intensity was recorded at 545 nm and normalized to the emission maximum.
4.3.2 Structural Analysis of MuHF-LBT with and without Tb(III)
The structures of apoMuHF-LBT and MuHF-LBT-Tb(III) were determined
by X-ray crystallography at  a 2.85 Å and 2.65 Å resolution,  respectively.
They both crystallized in I222 space group with 24 identical subunits in the
ASU with a solvent content of 64.7%. The overall X-ray-structure confirms
that the LBT does not affect the protein scaffold which superposes to the
native MuHF (pdb code 3WNW) with a rmsd value of 0.1 Å. However, the
LBT loop was not visible in any of the two structures. This is thought to be
due to high flexibility in the LBT. Temperature factors analysis shows a mean
B factor  of  57  Å2 calculated  for  the  main  chain  of  the  subunits  in  both
structures and 78 Å2 for the Tb(III) modeled in MuHF-LBT Tb(III) .
In order to confirm the presence or absence of Tb(III) in the crystals, X-ray
emission scans from 4.0 to 21.0KeV were performed. Characteristic peaks
corresponding  to  the  L  and  M  emission  lines  of  Tb(III)  were  clearly
identified  in  the  MuHF-Tb(III)  crystals  and,  as  expected,  absent  in  the
MuHF-LBT crystals. This allow confident modeling of Tb(III) in the electron
density maps.
In  MuHF-LBT  Tb(III)  structure,  24  Terbium  ions  were  positioned  and
successfully refined with a 75% occupancy in each ferroxidase site of the
protein  scaffold  and  eight  Terbium  ions  were  positioned  with  100  %
occupancy in each threefold axes. In the ferroxidase center; each Terbium ion
is located in a trigonal planar coordination to OE1-Gln141 and to OE1 and
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OE2-Glu62, and to OE2-Glu27, in a range 2.6-3.2 Å distance (Figure 4.20
A). In the threefold center, the Terbium ion is  tetrahedrally coordinated to
OE1- Glu134 of the three subunits, (at 2.2-2.4 Å distance) (Figure 4.20 B). In
the  4-fold  channels  one  water  molecule  each  were  positioned  and
successfully refined.
In an attempt to better describe the MuHF-LBT-Tb(III) a low resolution 7.1Å
electron  density  map  was  obtained  with  Cryo-EM.  The  final  3D map  of
MuHF-LBT-Tb(III) corresponds to an overall structure that conforms to the
high  resolution  crystallographic  data  indicating  perfect  matching  of  the
subunit assembly and helix axes. It is worth considering, from the analysis of
the selected 2D classes, that significant densities appear within the internal
cavity  that  can  be  attributed  to  the  LBT.  Nevertheless,  considerable
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Figure 4.20 –  Terbium binding sites from X-ray crystallography. The omit map
contoured at 3 σ is shown as a green mesh (A) In the ferroxidase center: a Tb(III),
is shown as a grey sphere and (B) in the threefold axes: the residues Glu131 and
Glu134 of three different monomers are depicted as sticks in light blue, cyan and
orange, respectively.
heterogeneity  of  the  observed  signals  does  not  allow  even  a  partial
reconstruction  of  at  least  a  single  conformation  of  the  24  LBTs.  Only,  a
kinked fragment of the terminal tail can be modeled, which corresponds to a
segment of 6-7 aminoacids (Figure 4.21).
Analysis  of  the  three-dimensional  structure  of  the  MuFt-LBT  Tb(III)
complex,  by  X-ray  crystallography  and  cryo-EM  demonstrates  that  the
presence of the C-terminal tag does not affect the overall assembly of the
protein  and  that  the  genetically  fused  tags  point  to  the  interior  cavity.
Furthermore, the peptide arm connecting the lanthanide binding loop to the
C-terminal sequence is flexible and does not allow for a complete resolution
of the local structure.
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Figure 4.21 –  3D postprocess final maps of MuHF-LBT Tb(III) from Cryo EM
analysis.  Data  were  obtained  with RELION  (Scheres,  2012).  Light  blue:  X-ray
diffraction  data  of  the  crystal  Terbium  structure.  Pink:  experimental  Cryo-EM
electronic density map. Map resolution: 7.1 Å . Scale bar: 10 Å . (A) external view;
(B) internal view; (C): focus on one internal C-terminal helix.
4.3.3 Uptake of MuHF-LBT by tumor cell lines 
After demonstration that MuHF-LBT-Tb(III) maintained the overall structure
of MuHF, its potential use as a imaging agent was tested. It is known that
MuHF  is  recognized  and  internalized  through  the  TfR1,  which  is
overexpressed  in  most  cancer  cells  lines  but  not  in  healthy  tissues.
Experiments on cells treated with the same amount (0.5 mg/mL) of MuHF-
LBT-Tb(III)  or  MuHF  were  undertaken  in  order  to  study  the  uptake
efficiency of cancer cells lines by flow cytometry and confocal microscopy.
However attempts to image live cells by direct excitation of the tryptophan
residue at  290-375 nm, yielded poor results  due to very high background
noise within Tb(III) emission interval. Thus, uptake efficiency was assessed
using FITC labeled ferritins.  As a baseline for FITC fluorescence,  control
cells untreated with FITC-ferritins were used.  In order to visualize MuHF-
LBT-Tb(III) nanocages within cytoplasm, cells were observed under confocal
microscopy. Confocal representative images of entire field of view of live
cells incubated with MuHF-LBT Tb(III) are shown in Figure 4.22 A. These
show that all tested cell lines (DU-145, HCT-116, MDA-MB-231 and SKOV-
3) successfully internalized both MuHF-LBT and MuHF-LBT to a similar
extent and highlight similar cellular distribution in the cytoplasm and in the
perinuclear space. These were further confirmed by flow-citometry analysis,
were similar percentage of cells with internalized ferritin were found (Figure
4.22 B).
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Figure 4.21 – Confocal microscopy images and flow cytometry analysis of MuHF-
LBT Tb(III) uptake by selected tumor cell lines. DU-145, HCT-116, MuHF- LBT
Tb(III)  or  MuHF  (0.5  mg/ml)  for  60  min.  A)  Images  acquired  by  confocal
microscopy showing side by side comparison of cellular  distribution of MuHF-
LBT-Tb(III)  and  MuHF  conjugated  with  FITC.  Scale  bar:  50  μm.  (B)  Flow
cytometry analysis of MuHF-LBT-Tb(III) and MuHF cellular uptake.
In conclusion, ferritin nanocage can be engineered to improve metal binding
properties by addition of an appropriate metal binding tag facing the cavity’s
interior at topologically selected locations. This approach is an alternative to
the quasi random metal cluster insertions into the ferritin cavity that has been
used either by free diffusion of metal ions through the open pores on the
protein  shell  or  by  disassembly  and  reassembly  of  the  protein  cage.  The
rational design of metal binding sites foster more advanced applications such
as  the  formation  of  up-converting  nanoparticles  (Wang  et  al.,  2011) or
ultrabright  fluorescent  organic  polymer  for  single  molecule  detection
(Grazon et al., 2013) – emerging techniques for live cell imaging.
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5 Conclusions
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The body of experimental results of the present work highlights the notable
properties  related  to  small  molecule  entry  into  prototypic  and genetically
engineered  archaeal  ferritin  homopolymers  that  are  relevant  both  to  the
general  mechanism  of  payload  encapsulation  into  ferritins  and  to  the
widespread  nanotechnological  applications  of  these  proteins.  The  current
view on ferritin three-dimensional structure has always been consistent with
the  idea  of  an  apparently  closed,  impermeable  structure,  in  which  the
communication between the internal cavity and the outer space is uniquely
governed  by  the  gating  effect  of  threefold  channels,  endowed  with
hydrophilic, negatively charged tunnels involved in iron uptake. This vision
is  consistent  with  the  analysis  of  accessible  surfaces  on  the  ferritin  shell
based on crystallographic data that envisage the protein matrix as an almost
uniform  barrier  that  impairs  even  the  diffusion  of  water  molecules.  In
contrast, the present data indicate clearly that the protein matrix in archaeal
ferritins does not provide a significant barrier against bulky ligands such as
DTNB, which, due to its dimensions (8-10 Å) and the net negative charge,
would never be able to cross the hydrophilic threefold channel, even though
the channels in archaeal ferritins are less negative than in the mammalian
ones.  These  findings  indicate  that  molecular  diffusion  into  ferritin  is  a
complex  phenomenon  that  most  likely  entails  the  formation  of  transient
openings at the intersubunit interfaces due to possible synchronous motions
of aminoacid side chains or,  as recently reported  (Zhang et  al.,  2017),  to
subunit rearrangements ascribable to “breathing motions” of the whole 24-
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mer. In this framework, the small molecule entry process can be envisaged as
a fully reversible one and fluxes of molecules in and out must simply obey
concentration  gradient  between  the  internal  cavity  and  the  external
environment.  In  our  experimental  approach,  the  small  molecule  release
outside  the  cavity  was  deliberately  abolished  by  formation  of  a  covalent
disulfide  bond  of  the  sulfidryl  reactive  molecule  and  a  cysteine  residue,
inserted  in  topologically  selected  position  inside  the  cavity.  In  the
experimental  set  up,  the kinetics  of  disulfide bond formation were in  the
order of tens of seconds, a time frame likely to reflect the slow crossing of
the  protein  matrix,  given the  tens  of  millisecond time frame required  for
bimolecular  disulfide  bond  formation.  At  present,  the  kinetics  of  small
molecule release has not been investigated, but is likely to be much slower,
possibly due to multiple interactions of the molecule within the surface of the
ferritin internal cavity. In summary, the so-called “encapsulation” process in
which ferritins are able to capture small molecules inside the cavity should be
rather considered as a “matrix-assisted binding” of the small molecule to the
surface of the internal cavity rather than a simple physical confinement.
Within this vision, the technological effort of protein engineering for payload
delivery  may  be  most  conveniently  addressed  to  modification  of  the
properties  of  the  surface  of  the  internal  cavity  rather  than  to  possible
rearrangements of classical threefold channels. In this framework, the unique
properties of AfFt are a prominent example of ferritin versatility and offer the
opportunity  of  completely  bypassing  complications  due  to  protein  cavity
accessibility  and  24-mer  disassembly.  AfFt  in  fact  represents  a  uniquely
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suitable scaffold for incorporating a range of diverse substructures inside the
protein cavity, either by assembly/disassembly process at neutral pH or by
diffusion  through  the  large  triangular  pores  on  the  surface.  Complete
understanding of AfFt assembly process is however crucial in order to exploit
the potentiality of this protein for biomedical applications. In this work, the
effect of divalent cation on protein assembly has been clearly singled out,
thus demonstrating that physiological Mg2+ concentrations are necessary and
sufficient to promote full assembly of the 24-mer. At present, however, the
effect of divalent cations on polymerization has not been explained as yet in
terms of mechanism. The most likely hypothesis might entail cations binding
to  the  iron  binding  sites  on  the  dimeric  species  that  promotes  a
conformational  change  leading  to  exposure  of  sticky  ends  capable  of
interdimers  association  into  higher  molecular  weight  species.  In  this
framework,  AfFt  polymerization  may  possibly  follow  the  same  pathway
identified for cations induced viral capsid assembly. 
Nevertheless, one of the key properties of ferritin nanocages in biomedical
applications  is  the  possibility  of  targeting  receptors  on  human  cells,  thus
allowing the delivery of the desired payload within the cytoplasm. In this
respect, HumAfFt, here described as humanized archaeal ferritin, combines
the versatility of assembly and cargo incorporation of AfFt with binding to
TfR1 and cellular uptake of HuHF. As a matter of fact, the term “humanized”
is a misnomer, as HumAfFt contains just a stretch of aminoacids displayed in
the external loop of HuHF, that is necessary and sufficient for TfR1 binding.
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Further  mutations  will  be  necessary  in  order  to  make  HumAfFt
immunologically similar, if ever possible, to HuhF.
On  a  different  strategy,  grafting  diverse  functionalities  on  mammalian
ferritins, while preserving immunological properties of the native protein, can
be allowed by insertions of polypeptide segments within the internal cavity.
In particular, the short C-terminal helix, located in proximity of the fourfold
symmetry axis, represents a privileged topological region for adding novel
functional properties through simple extension of the aminoacid sequence.
Thus, a well characterized lanthanide binding sequence has been engineered
at the C-terminal end of the MuHF in order to build a new carrier endowed
with the notable property of chelating a terbium atom inside the cavity within
a defined spatial position and stoichiometry and not quasi-randomly oriented
as for iron oxide during the iron core formation. Besides the obvious use of
lanthanide  containing  ferritin  for  diagnostic  (e.g.  Gadolinium  for  MRI
imaging) or therapeutic (177Lu as a radioemitting tool), the rationale for such
engineering consisted in the first step for the set up of a new scaffold for
further multifunctional polymetallic nanoparticles. The spatial  confinement
of 24 lanthanide atoms in proximity of the fourfold axis will in fact allow the
possibility of placing other different elements that are capable of efficient
energy transfer with the lanthanide itself. Such elements might be fluorescent
organic antenna systems endowed with high photon absorption cross section
(to  compensate  the  limited  light  harvesting  properties  of  lanthanide)
encapsulated  within  the  ferritin  cavity.  This  strategy  could  be  used  to
generate highly absorbing hot spots that transfer energy to the lanthanide ion
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and exploit  the intrinsic narrow band emission of the lanthanide itself.  In
addition, according to the same strategy, multi lanthanides could be hosted
and generate up-converting photosystems through a two photon absorption
process (by one species of lanthanide) whose energy is transferred to a single
emitting  ion  at  doubled  energy.  The  synthesis  of  such  innovative  up-
converting nanoparticles carrying with them the water solubility, stability and
cell  targeting  properties  of  ferritins  is  currently  ongoing  and  promises  to
become a smart tool not only in cell imaging applications but also in most
advanced photonics applications (water soluble nanophosphors).
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6 Abbreviations
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ADC Antibody-drug conjugates
AfFt Archaeoglobus. fulgidus ferritin 
ASU Asymmetric unit
Bfr Bacterioferritin
CCMV Cowpea chloroticmoottle virus
CD Cluster of differentiation
cryo-ET Electron cryotomography
cryo-TEM Cryo transmission electron microscopy
CTF Contrast transfer function 
DDS Drug-delivery systems
DLS Dynamic light scattering
DMEM Dulbecco's Modified Eagle Medium
Dps DNA-binding protein from starved cells 
DTNB 5,5’-dithio-bis-(2-nitrobenzoic acid)
EDTA Ethylenediaminetetraacetic acid
EPR Enhanced permeability and retention
ESRF European Synchrotron Radiation Facility
FACS Fluorescence activated cell sorting 
FBS Fetal bovine serum
FITC Fluorescein-isothiocyanide
FOC Ferroxidase center
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FRET Forster resonance energy transfer
FSC Fourier shell correlation
GSPG4 Chorndroitin sulfate proteoglycan 4
HA Heamagglutinin
HBV Hepatitis B virus
HoSP Horse spleen ferritin
Hsp Heatshock Protein
HuHF Human H-chain ferritin
HuLF Human L-chain ferritin
HumAfFt Humanized A. fulgidus ferritin
IPTG Isopropyl β-D-1-thiogalactopyranoside
ITC Isothermal titration calorimetry
LB Luria-Bertani
LBT Lanthanide binding peptide
LC-MS Liquid Chromatography – Mass Spectrometry
mAb Monoclonal antibodies
MRI Magnetic resonance imaging
MuHF Mouse H chain ferritin
PAA Polyacrylic acid 
PBS Phosphate-buffered saline
PCR Polymerase chain reaction
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PfFt Pyrococcus furiosus ferritin
rmsd root mean square deviation
ROS Reactive oxygen species
SAXS Small-angle X-ray scattering
Scara5 mouse scavenger receptor class A member 5
SEC Size-exclusion chromatography
TB Trypan Blue
TCEP Tris (2-carboxyethyl) phosphine 
Tf Transferrin
TfR1 Human transferrin receptor 1
TIM-2 T-cell immunoglobuline and mucin domain containing receptor 2
TNB 5-thio-2-nitro-benzoic acid
US-FDA United States Food and Drug Administration
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